[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1996003501A1 - Dual hybrid system - Google Patents

Dual hybrid system Download PDF

Info

Publication number
WO1996003501A1
WO1996003501A1 PCT/EP1995/002724 EP9502724W WO9603501A1 WO 1996003501 A1 WO1996003501 A1 WO 1996003501A1 EP 9502724 W EP9502724 W EP 9502724W WO 9603501 A1 WO9603501 A1 WO 9603501A1
Authority
WO
WIPO (PCT)
Prior art keywords
domain
transcription
dna
fragment
feature
Prior art date
Application number
PCT/EP1995/002724
Other languages
French (fr)
Inventor
Bhabatosh Chaudhuri
Christine Stephan
Peter Fürst
Original Assignee
Ciba-Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba-Geigy Ag filed Critical Ciba-Geigy Ag
Priority to EP95925863A priority Critical patent/EP0775206A1/en
Priority to JP8505403A priority patent/JPH11506301A/en
Priority to AU29832/95A priority patent/AU2983295A/en
Publication of WO1996003501A1 publication Critical patent/WO1996003501A1/en
Priority to FI970205A priority patent/FI970205A/en
Priority to NO970258A priority patent/NO970258L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • Phosphatases and kinases are enzymes that are generally involved in the regulation of enzyme activity by adding or removing of phosphate groups to enzymes.
  • the activity of these enzymes is often regulated by the binding of another protein and/or by an autoinhibitory domain. This binding of the autoinhibitory domain again is regulated, e.g., by a peptidic or non-peptidic compound that binds to the autoinhibitory domain.
  • a protein phosphatase of the 2B subfamily one of four classes of phosphoserine/ phospho- threonine-specific phosphoprotein phosphatases that have been distinguished on the basis of their sensitivities to inhibitors and divalent cations, is calcineurin.
  • Calcineurin is the only known phosphatase that is regulated specifically by Ca 2+ and calmodulin.
  • the calcineurin holoenzyme purified from mammalian cells (Guerini et al., Proc. Natl. Acad. Sci. USA (1989), 86, 9183-9187) is a heterodimer consisting of a large catalytic subunit (51-61kD) and a small regulatory subunit ( ⁇ 19kD).
  • the catalytic subunit binds calmodulin, and the regulatory subunit attaches up to four molecules of Ca 2+ .
  • the catalytic activity of the calcineurin holoenzyme is completely inhibited by a synthetic peptide corresponding to a region in the C-terminus of the catalytic subunit in the presence of Ca + -calmodu!in. This suggests that the catalytic subunit contains an autoinhibitory domain (AID) (Hashimoto et al., J. Biol. Chem. (1990), 265, 1924-1927).
  • the budding yeast Saccharomyces cerevisiae contains proteins with properties similar to the mammalian catalytic and regulatory subunits of calcineurin.
  • yeast cells possess two genes, CNA1 and CNA2, which encode for the mammalian catalytic subunit (Cyert et al., Proc. Natl. Acad. Sci. USA (1991), 88, 7376-7380).
  • CNA1 and CNA2 proteins contain regions which have similarity to the putative AID sequence of the mammalian enzyme (Hashimoto etai, J. Biol. Chem. (1990), 265, 1924-1927).
  • Cyclosporin A is an undecapeptide (Schreiber, Science (1991 ), 251 , 283-287) and acts as an inhibitor of T-cell activation. It is currently the favored therapeutic agent for prevention of graft rejection after organ and bone marrow transplantation. CsA binds to family of conserved proteins, named cyclophilins, having high affinity for CsA (Schreiber, Science (1991), 251 , 283-287).
  • FK506 a macrolide; Liu, Immunol. Today (1993), 14, 290-295) has been discovered that also inhibits T-cell activation.
  • FKBPs FK-binding proteins
  • PKA cAMP dependent protein kinase
  • This enzyme is a member of the large group of eukaryotic protein kinases that play critical roles in regulation of cell growth and comprises a catalytic and a regulatory subunit.
  • PKA in its inactive state consists of a tetramer consisting of two identical catalytic and two identical regulatory subunits.
  • This enzyme is activated, like the other protein kinases, by dissociation of the regulatory and the catalytic subunit to form a dimer of active catalytic subunits. This dissociation is mediated, e.g., by cAMP.
  • p70S6 a single chain enzyme involved in the regulation of protein synthesis.
  • the target for p70S6 is the 40S ribosomal protein S6. It is supposed that phosphorylation of S6 either triggers or facilitates the activation of protein synthesis.
  • p70S6 is supposed to be regulated by an autoinhibitory domain at the C-terminus (Flotow et al., J. Biol. Chem., (1992), 267, 3074-3078) and through serine/threonine phosphorylation by insulin/mitogen-activated protein kinases.
  • a new approach for the detection of protein-protein interaction is the two-hybrid system (Fields et al., Nature (1989), 340, 245-246).
  • This system provides a convenient method in which the possible interactions between a peptide and a protein can be examined in a cellular environment.
  • the system depends on the reconstitution of a transcription factor from its two essential components, the DNA-binding domain and its activating sequence.
  • two fusion proteins are generated, each comprising one of the two domains of the transcription factor and one of the two proteins that are being tested for their ability to bind to each other. Only when the proteins to be tested interact, a functional transcription reconstitutes.
  • the activation of gene transcription varies. To monitor the formation of a functional transcription factor, the expression of the gene triggered by said reconstituted transcription factor is measured.
  • this dual-hybrid approach is capable of determining the interaction between a phosphatase or a kinase and its autoinhibitory domain (AID).
  • AID autoinhibitory domain
  • inventive approach it is su ⁇ risingly possible to measure the influence of antagonists and agonists and, hence, to find new regulatory polypeptides and to design regulatory polypeptides with increased regulatory properties. It has been su ⁇ risingly found, for example, that cyclosporin A and FK506 despite their different structure inhibit the formation of active-center-AID-complex.
  • inventive method it is su ⁇ risingly possible to identify new agonists or antagonists of a phosphatase or a kinase. Additionally, it has been found su ⁇ risingly that autoinhibitory domains exhibit better binding properties when present in several copies.
  • the current invention concems a transcription system for measuring the interaction between a phosphatase or kinase, or a mutein or fragment thereof that binds an autoinhibitory domain, with said autoinhibitory domain, comprising a) the DNA binding domain of a transcription factor and the transcription activation domain of a transcription factor that are separated, wherein one of the two transcription factor domains is linked to a polypeptide comprising a phosphatase or kinase or a fragment thereof that binds an autoinhibitory domain; and the other of the two transcription factor domains is linked to a polypeptide comprising an autoinhibitory domain that is capable of binding to the polypeptide linked to the first transcription factor domain, and b) a DNA that is transcribed when the DNA binding domain of said transcription factor and the transcription activation domain of said transcription factor are connected via the polypeptides linked thereto.
  • a transcription system for measuring the interaction between a phosphatase or kinase, or a mutein
  • a preferred phosphatase or kinase comprises an autoinhibitory domain (AID) that can be located on the catalytic or a regulatory subunit.
  • a phosphatase or kinase are phosphatase A1 and A2B, cyclic GMP dependent kinase (cGPK), myosin light chain kinase (MLCK), myosin heavy chain kinase, dsRNA-dependent kinase, dsDNA-dependent kinase, protease activated kinase I and II, cell cycle kinase cdc-28 MPF, growth factor regulated kinase, mammary gland casein kinase, glycogen synthase kinase-3, AMP activated protein kinase, pyruvate dehydrogenase kinase, branched chain ⁇ -ketoacid dehydogenase kinase, end
  • a form of said phosphatase or kinase or a mutein or fragment of said phosphatase or kinase that has a free AID binding domain In this form the AID that is part of the original enzyme is not bound to the catalytic domain. This form can be achieved via phosphorylation, lack of certain deactivating factors, addition of activation factors or via a mutein that does not comprise a functional AID.
  • the AID can be inactivated using several approaches. It is, for example, possible to delete the AID on DNA-level, to alter the AID by mutagenesis to be inactive or to use only a fragment of the protein that does not comprise the AID.
  • the mutein is not changed to such an extent that the autoinhibitory domain used in the dual hybrid test cannot bind anymore. It is, for example, possible to use a fragment of calcineurin that lacks the C-terminal AID, especially the C-terminal 40-60 amino acids.
  • Autoinhibitory domains that interact with or bind to a phosphatase or kinase are well known in the art.
  • the interaction of these autoinhibitory domains and the corresponding enzymes by formation of a complex is sensitive to various parameters like compounds that compete with the autoinhibitory domain for the same attachment site, compounds that change the affinity of the autoinhibitory domain for the attachment site or compounds that change the affinity of the attachment site for the autoinhibitory domain.
  • These compounds can be, for example, peptides, chemical compounds, metal salts or compounds comprising peptidic and non-peptidic parts.
  • Examples for known regulatory compounds are DNA, RNA, steroids, macrolides, cAMP, cGMP, calmodulin, phosphatidyl serine, diacyl glycerol, insulin, epidermal growth factor, interleukins, cytokines, growth factors like IGF and GMCSF, and Ca 2 ⁇ Preferred examples for such autoinhibitory domains are the inhibitory or auto ⁇ inhibitory domains of the catalytic or regulatory subunit of a phosphatase or kinase (Kemp et al., Trends in Biochem. Sci. (1990), 15, 342-346), e.g.
  • the autoinhibitory domain and the fragment that binds an autoinhibitory domain originate from the same enzyme komplex.
  • the autoinhibitory domain and the fragment that binds an autoinhibitory domain originate from the same enzyme.
  • artificial substrates or pseudosubstrates of the phosphatase or kinase to be tested are also included.
  • Pseudosubstrates are, for example, created by replacing amino acids of natural occurring autoinhibitory domains with amino acids that promote binding to the enzyme. Examples are the replacement of one or more serine, threonine and/or thyrosine by another amino acid like alanine (Hardie, Nature (1988), 335, 592-593).
  • a preferred polypeptide that binds to the phosphatase or kinase as described above is a polypeptide comprising the regulatory subunit of PKA, the autoinhibitory domain of calcineurin and or p70S6 kinase, as well as fragments thereof capable of binding to enzyme in the test.
  • the regulatory subunit of PKA a fragment of calcineurin comprising the C-terminal 40 to 60 amino acid and a fragment of p70S6 kinase comprising amino acid 332 to 502 or 399 to 502.
  • the autoinhibitory domain can be linked to the transcription factor domain as a single copy or in several copies which is preferred, e.g., 1 to 5 copies of the AID or 2 to 4 copies which is preferred. It is also possible to link different autoinhibitory domains to the same transcription factor to test, e.g., different influences.
  • the different autoinhibitory domains or the copies of the same autoinhibitory domain may be connected directly or with spacer groups. Spacer groups are, for example, ⁇ -helix breakers like short peptides of repeated amino acids like Gly 3 , Gly 4 or Gly 5 .
  • Transcription factors are proteins that bind to a certain region of DNA (promoter) and initiate the transcription of a DNA sequence that belongs to it. These transcription factors usually comprise a domain that is responsible for the DNA recognition or binding and a domain that initiates transcription. DNA recognition and transcription initiation domains are known for several transcription factors such as Ace1 , Gal4, VP16, p53 and lexA.
  • both domains necessary for transcription initiation of a certain gene can originate from two different transcription factors or from the same transcription factor.
  • both domains may originate form the CUP1 or Gal4 transcription factor or the DNA binding domain originates from the lexA transcription factor and the transcription activating domain originates from the VP16 or p53 transcription factor; or any other combination thereof.
  • the DNA binding domain is located in the region comprising N-terminal amino acids, preferred are the N-terminal 122 amino acids, and the transcription activation domain is located in the region comprising C-terminal amino acids, wherein the C-terminal 100 amino acids are preferred, (Cizewski et al., Proc. Natl. Acad. Sci. USA (1988), 86, 8377-8381).
  • one of the two transcription factor domains is linked to a polypeptide comprising a phosphatase or kinase or a fragment thereof that binds an autoinhibitory domain, as described above.
  • the other of the two transcription factor domains is linked to a polypeptide comprising an autoinhibitory domain that is capable of binding to the phosphatase or kinase linked to the first transcription factor domain, as described above.
  • a further aspect of the invention is an expression cassette for the expression of a fusion protein comprising the DNA binding domain or the transcription activation domain of a transcription factor and a polypeptide comprising a phosphatase or kinase or a fragment thereof that binds an autoinhibitory domain; or a polypeptide comprising said autoinhibitory domain or an active fragment thereof that is capable of binding to said phosphatase or kinase or a fragment thereof.
  • Another aspect of the current invention is a DNA that is transcribed when the DNA binding domain of a transcription factor and the transcription activation domain of a transcription factor are joined via the polypeptides linked thereto, as described above, if this DNA is not already part of the natural genome of the host that is used for the test.
  • This DNA is usually comprised in an expression cassette comprising a promoter that is operably linked to said DNA and to a sequence containing a transcription termination signal, as described above.
  • said DNA is coding for a polypeptide.
  • the promoter of the expression cassette is chosen in accordance with the transcription factor fragment used.
  • suitable transcription factor/promoter combinations are Ace1/CUP1p or Gal4/Gal1-Gal10p (Chien et al., Proc. Natl. Acad. Sci. USA (1991), 88, 9578-9582; Yang et al., Science (1993), 257, 680-682).
  • the promoter is the CUP1 promoter.
  • a suitable DNA that is transcribed under the control of this promoter usually causes an effect that can be measured easily during or after transcription or translation.
  • transcription or translation products that can be measured easily e.g. via the measurement of the amount of protein, mRNA or DNA produced; or that cause an effect that can be measured easily, e.g. cell growth, an enzymatic reaction or color.
  • the transcribed DNA codes, for example, for a protein that is produced in an amount that is related to the amount of activation of said promoter and that is, e.g., not produced elsewhere in the chosen microbiological host under the applied conditions.
  • suitable proteins are the metallothionein that is encoded by the yeast CUP1 gene, ⁇ -galactosidase or luciferase. Preferred is metallothionein and ⁇ -galactosidase.
  • An expression cassette for said suitable DNA may be already present in the microbiological host.
  • the corresponding original transcription factor is inactivated or replaced by the inventive transcription factor fusion constructs.
  • the reconstitution of the promoter will induce the transcription of a genuine gene, that is, e.g., necessary for survival of the microbiological host under the condition applied.
  • An example is the replacement of the original Ace1 domain(s) with the separated Ace1 domain(s) modified according to the invention, resulting in a yeast whose sensitivity to Cu + depends on the reconstitution of the functional Ace1.
  • a microbiological host transformed with this inventive system will, for example, grow in Cu 2+ containing media only if the two transcription factor domains are linked via the associated phosphatase or kinase, as defined above, and the associated autoinhibitory domain of this phosphatase or kinase, as defined above.
  • the promoter is operably linked to the encoded protein. Additional sequences, such as pro- or spacer-sequences which may or may not carry specific processing signals can also be included in the constructions to facilitate accurate processing of precursor molecules. Altematively fused proteins can be generated containing internal processing signals which allow proper maturation in vivo or in vitro.
  • the expression cassettes according to the present invention comprise also the 3'-flanking sequence of a gene which contains the proper signals for transcription termination and polyadenylation. Suitable 3'-flanking sequences are for example those of the gene naturally linked to the promoter used, or 3'-flanking sequences of other yeast genes, e.g., of the PHO5 or the SUC2 gene.
  • An expression cassette comprising the DNA that is transcribed under the control of the inventive transcription factor construct may, for example, contain additionally a DNA sequence encoding a signal peptide.
  • the expression cassettes for the transcription factor fusion proteins and the DNA that is transcribed by the reconstituted transcription factor may be present on different plasmids or some or all together on one plasmid.
  • These plasmids may be integrated into the genome of the microbiological host or may retain as separate units. It is for example possible to integrate the expression cassettes for the modified transcription factor domains into the genome of the microbiological host, e.g. at the position of the original transcription factor domains and inactivating therewith the original factor, as described in (Munder & F ⁇ rst, Mol. Cell. Biol. (1992), 12, 2091-2099).
  • the expression cassette expressing the polypeptide to be monitored may be inserted, if it is not already part of the genome of the microbiological host, in form of a stable plasmid, e.g., in Saccharomyces cerevisiae in form of a two-micron based plasmid as described in EP-341215.
  • hybrid vectors according to the invention are selected from the group consisting of a hybrid plasmid and a linear DNA vector and are further selected depending on the host organism envisaged for transformation.
  • the invention relates also to hybrid vectors comprising the expression cassettes described above.
  • Hybrid plasmids that retain as separate units carry the expression cassettes according to the invention and as additional DNA sequences a yeast replication origin and a selective genetic marker for yeast.
  • Hybrid plasmids containing a yeast replication origin e.g. an autonomously replicating segment (Ars)
  • a yeast replication origin e.g. an autonomously replicating segment (Ars)
  • a yeast replication origin e.g. an autonomously replicating segment (Ars)
  • Hybrid plasmids containing sequences homologous to yeast 2 ⁇ plasmid DNA can be used as well. These hybrid plasmids will get integrated by recombination into 2 ⁇ plasmids already present within the cell or will replicate autonomously. 2 ⁇ sequences are especially suitable for high- frequency transformation plasmids and give rise to high copy numbers.
  • the preferred hybrid plasmids according to the invention may include a DNA sequence as part of a gene present in the host yeast chromosome (e.g. the gene for the transcription factor domain or its promoter linked to the transcription factor constructs).
  • a DNA sequence as part of a gene present in the host yeast chromosome (e.g. the gene for the transcription factor domain or its promoter linked to the transcription factor constructs).
  • the homologous sequence which should amount to a stretch of at least 20 to 100 deoxynucleotides, the whole plasmid or linear fragments thereof can be stably inco ⁇ orated into the host chromosome by recombination.
  • the progeny cells will retain the introduced genetic material even without selective pressure.
  • any marker gene can be used which facilitates the selection for transformants due to the phenotypic expression of the marker.
  • Suitable markers for yeast are particularly those expressing antibiotic resistance or, in the case of auxotrophic yeast mutants, genes which complement host lesions. Corresponding genes confer, for example, resistance to the antibiotic cycloheximide or provide for prototrophy in an auxotrophic yeast mutant, for example the URA3, LEU2. HIS3 or TRP1 gene. It is also possible to employ as markers structural genes which are associated with an autonomously replicating segment providing that the host to be transformed is auxotrophic for the product expressed by the marker.
  • the additional DNA sequences which are present in the hybrid plasmids according to the invention also include a replication origin and a selective genetic marker for a bacterial host, especially Escherichia coli.
  • a replication origin and a selective genetic marker for a bacterial host, especially Escherichia coli.
  • an E. coli replication origin and an E. coli marker in a yeast hybrid plasmid.
  • large amounts of hybrid plasmid DNA can be obtained by growth and amplification in E. coli and, secondly, the construction of hybrid plasmids is conveniently done in E. coli making use of the whole repertoire of cloning technology based on E. coli.
  • E. coli plasmids, such as pBR322 and the like contain both E. coli replication origin and E. coli genetic markers conferring resistance to antibiotics, for example tetracycline and ampiciilin, and are advantageously employed as part of the yeast hybrid vectors.
  • vector DNA which together with the yeast promoter and the coding region is forming a hybrid plasmid according to the invention.
  • vector DNA which together with the yeast promoter and the coding region is forming a hybrid plasmid according to the invention.
  • vector DNA which together with the yeast promoter and the coding region is forming a hybrid plasmid according to the invention.
  • the preferred hybrid vectors of the present invention are prepared by methods known in the art, for example by linking a suitable promoter, a coding region, the 3' flanking sequence of a yeast gene and optionally vector DNA.
  • vector DNA for example bacterial plasmid DNA or the like (see above), having at least one restriction site, preferably two or more restriction sites, can be employed.
  • the vector DNA already contains replication origins and gene markers for yeast and/or a bacterial host.
  • the vector DNA is cleaved using an appropriate restriction endonuclease.
  • the restricted DNA is ligated to the DNA fragment containing the yeast promoter and to the DNA segment coding for the desired protein.
  • restriction and ligation conditions are to be chosen in such a manner that there is no interference with the essential functions of the vector DNA and of the promoter.
  • the hybrid vector may be built up sequentially or by ligating two DNA segments comprising all sequences of interest.
  • Blunt ends (fully base- paired DNA duplexes) produced by certain restriction endonucleases may be directly ligated with T4 DNA ligase. More usually, DNA segments are linked through their single-stranded cohesive ends and covalently closed by a DNA ligase, e.g. T4 DNA ligase.
  • T4 DNA ligase e.g. T4 DNA ligase.
  • Such single- stranded "cohesive termini” may be formed by cleaving DNA with another class of endonucleases which produce staggered ends (the two strands of the DNA duplex are cleaved at different points at a distance of a few nucieotides).
  • Single strands can also be formed by the addition of nucieotides to blunt ends or staggered ends using terminal transferase ("homopolymeric tailing") or by simply chewing back one strand of a blunt- ended DNA segment with a suitable exonuclease, such as I exonuclease.
  • a further approach to the production of staggered ends consists in ligating to the blunt-ended DNA segment a chemically synthesized linker DNA which contains a recognition site for a staggered-end forming endonuclease and digesting the resulting DNA with the respective endonuclease.
  • the components of the hybrid vector according to the invention such as the yeast promoter, the structural gene optionally including a signal sequence, transcription terminator, the replication system etc., are linked together in a predetermined order to assure proper function.
  • the components are linked through common restriction sites or by means of synthetic linker molecules to assure proper orientation and order of the components.
  • a linear DNA vector is made by methods known in the art, e.g. linking the above yeast promoter to the coding region in such a manner that the coding region is controlled by said promoter, and providing the resulting DNA with a DNA segment containing transcription termination signals derived from a yeast gene.
  • Joining of the DNA segments may be done as detailed above, viz. by blunt end ligation, through cohesive termini or through chemically synthesized linker DNAs.
  • the DNA fragments coding for fragments or domains of polypeptides can be isolated by methods known in the art. It is for example possible to isolate the desired fragment from a gene bank using specific hybridization probes, to synthesize the desired fragment in a DNA synthesizer, to amplify the specific fragment via PCR techniques or to use any combination thereof.
  • Excision of a portion of a DNA coding for a protein-domain like the transcription activation or the DNA binding domain of a transcription factor, or a phosphatase or kinase lacking the autoinhibitory domain may be effected by using restriction enzymes.
  • a prerequisite of this method is the availability of appropriate restriction sites in the vicinity of the ends of the DNA coding for the desired domain.
  • the latter is advantageously contained in a greater DNA segment provided with appropriate linkers which allow insertion and cloning of the segment in a cloning vector.
  • a preferred microbiological host for the constructs described above is a yeast or bacterial cell, wherein yeast is more preferred and Saccharomyces cerevisiae is especially preferred.
  • the expression cassettes or hybrid vectors described above can be integrated into the microbiological host by standard methods in genetic engineering.
  • the microbiological host originating therefrom comprises one or more expression cassettes for the two modified transcription factors and one ore more expression cassettes expressing the polypeptide to be monitored.
  • the transcription system according to the invention or the host transformed therewith can be used for the identification of an agonist or antagonist of a phosphatase or kinase as described above.
  • the inventive transcription system can be used to identify an antagonist of the phosphatase or kinase as described above.
  • a further embodiment of the invention is a method for the identification of a phosphatase or kinase agonist and antagonist comprising a) treating a transformed microbiological host as defined above with a test compound, and b) measuring the amount of transcription activation caused by the two modified transcription factor fragments, e.g. by measuring the amount of a produced mRNA, DNA, protein or by measuring an effect caused by the induced transcription or translation product.
  • the agonist and antagonist identified using the inventive system have valuable pharmacological properties an can be used in a method of treatment. Indications for these agonists and antagonists are, for example, cancer, arthritis, psoriasis, graft rejection, autoimmune diseases, allergy, Alzheimer's disease and regulation of cell proliferation. It is, for example, possible to use the calcineurin antagonists in a method of treatment that is characterized by inhibiting T-cell activation, especially in a method of treatment or prevention of graft rejection. Also enclosed by the present invention is a pharmaceutical composition comprising one or more of the compounds identified by the inventive system or pharmacologically acceptable salt thereof, optionally together with pharmacologically suitable carrier.
  • Fig. 1 is a schematic illustration of plasmid pRH1.
  • Fig. 2 is a schematic illustration of plasmid pRH14C.
  • Fig. 3 is a schematic illustration of plasmid YipCL.
  • Fig. 4 is a schematic illustration of plasmid pMH7.
  • Fig. 5 is a schematic illustration of plasmid pMH10.
  • the enzyme employed for all PCR reactions is Vent polymerase (New England Bio-Labs)
  • the Primers are synthesized on a DNA synthesizer
  • Example 1 Isolation of vCNA1 and vCNA2 yCNA1 and yCNA2 are the complete genes from the yeast genome encoding the two isozymes for the catalytic subunit of yeast calcineurin.
  • PCR polymerase chain reaction
  • yeast genomic DNA obtained from the wild type strain S288C
  • primers SEQ ID NOs 1 , 2 and 3, 4.
  • the primers correspond to the published sequences of yeast CNA1 and CNA2 (Cyert et al., Proc. Natl. Acad.
  • the yeast cDNA is amplified in 30 cycles of PCR.
  • the Bglll-Hindlll fragments containing the coding regions of yCNA1 and yCNA2 are ligated to the plasmid pUC19Bgl, completely digested with Bglll/Hindlll.
  • An aliquot of the ligation mixture is added to calcium- treated, transformation-competent E. coli HB101 cells, ⁇ ampicillin resistant E. coli transformants from each of the two transformations are grown in the presence of 100 mg l ampicillin.
  • Plasmid DNA is prepared and analyzed by digestion with Bglll/Hindlll, Bglll/BstEII and Hindlll/BstEII.
  • the two correct clones with the expected fragments are named pUC19Bgl/Bglll-Hindlll/yCNA1 and pUC19Bgl/Bglll-Hindlll/yCNA2, respectively.
  • the DNA inserts in the two plasmids are confirmed by sequencing (using the Applied Biosystems DNA sequencer 370A).
  • the vector pUC19Bgl used for the above ligations, is a modified pUC19 (Boehringer Mannheim GmbH, Germany).
  • pUC19 is digested with the restriction enzyme BamHI and the sticky ends are flushed with the large fragment of Klenow polymerase.
  • the blunt ended DNA is ligated with Bglll linkers (double-stranded octamers, the sense strand being 'CAGATCTG'; Boehringer), digested with Bglll and religated.
  • An aliquot of the ligation mixture is transformed in HB101 cells. Plasmid DNA is prepared from 6 HB101 transformants and are analyzed by digestion with Scal/Bglll and Scal/BamHI.
  • pUC19Bgl One correct clone with the expected fragments is named pUC19Bgl.
  • the BamHI and Bglll restriction sites are both present in the vector pUC19Bgl.
  • the plasmid pUC18Bgl is prepared in an identical manner from pUC18.
  • Example 2 Construction of vCNAI ⁇ and vCNA2 ⁇ , C-terminal truncated versions of the genes encoding the isozymes (i.e. vCNA1 and vCNA2) for the catalytic subunit of yeast calcineurin
  • PCR is performed on the complete yeast CNA1 and CNA2 (pUC19Bgl/ Bglll-Hindlll/ yCNA1 and pUC19Bgl/Bglll-Hindlll/yCNA2, as templates; see Example 1 ), using two pairs of deoxyoligoribonucleotides as primers (see SEQ ID NOs 1 , 5 and 2, 6).
  • the yeast cDNA is amplified as described in Example 1. Two 1670 bp and 1530 bp Bglll-Hindlll fragments, encoding yCNAI ⁇ and yCNA2 ⁇ (i.e.
  • yCNA1 and yCNA2 lacking their putative autoinhibitory domains are isolated. After digestion with Bglll/Hindlll, the fragments are ligated to the plasmid pUC19Bgl (see Example 1). DNA obtained from transformants are analyzed as described in Example 1). The two correct clones with the expected fragments are named pUC19Bgl/Bglll-Hindlll/yCNA1 ⁇ and pUC19Bgl/Bglll- Hindlll/yCNA2 ⁇ , respectively. The truncated gene fragments are confirmed by sequencing, as in Example 1.
  • Example 3 Construction of vKAID) and v2(AID), the gene fragments encoding the autoinhibitory peptides of yeast calcineurin vCNA1 and vCNA2
  • the Bglll-Xbal autoinhibitory sequences y1 (AID) and y2(AID) (Cyert et al., Proc. Natl. Acad. Sci. USA (1991), 88, 7376-7380), are obtained by PCR using pUC19Bgl/Bglll-Hindlll/yCNA1 and pUC19Bgl/Bglll-Hindlll/yCNA2, as templates (see Example 1).
  • the primers employed are depicted in SEQ ID NOs 7, 8 and 9, 10.
  • the Bglll-Xbal fragments are subcloned in pUC19Bgl.
  • the two clones with correct inserts are named pUC19Bgl/Bglll-Xbal/y1 (AID) and pUC19Bgl/Bglll-Xbal/y2(AID), respectively.
  • the SUC2 gene (Taussig et al., Nucleic Acids Res. (1983), 11 , 1943-1954) terminator is isolated as four unique fragments (-300 bp) by PCR, using yeast genomic DNA as template: (i) an EcoRI-Sacl fragment with primers in SEQ ID NOs 11 and 12; (ii) an Xbal- Sacl fragment with primers in SEQ ID NOs 13 and 12; (iii) a Bglll-Sacl fragment with primers in SEQ ID NOs 14 and 12; (iv) an EcoRI-Kpnl fragment with primers in SEQ ID NOs 11 and 15. All the three fragments are subcloned in pUC19 or pUC19Bgl and the DNA inserts are confirmed by DNA sequencing (see Example 1). The resulting plasmids are:
  • a 393 bp truncated version of the constitutive glyceraldehyde dehydrogenase promoter (GAPCLp) is cloned as a -670 bp Sall-EcoRI fragment (Meyhack et al., in Hershberger, Queener, Hegeman (ed.), Genetics and molecular biology of industrial microorganisms, 1989, p. 311-321. American Society for Microbiology, Washington, DC) into pBluescriptllKS- vector (Stratagene), yielding the plasmid pRH2.
  • the -670 bp Sall-EcoRI insert in pRH2 contains a 276 bp Sall-BamHI fragment from pBR322 upstream of the GAPCLp.
  • a 80 bp EcoRI-Spel double-stranded DNA linker (see SEQ ID NO 16), encoding the nuclear localization signal (NLS) from the simian virus 40 Tantigen (Kalderon et al., Cell (1984), 39, 499-509; and Nelson et al., Mol. Cell. Biol. (1989), 9, 384-389), is subcloned in pRH2 and the DNA insert is confirmed by sequencing (see Example 1 ).
  • One correct clone is referred to as pRH3.
  • the -304 bp Xbal-Bglll ACE1C transcriptional activation domain from the yeast transcriptional activator ACE1 (Munder et al., Mol. Cell. Biol. (1992), 12, 2091-2099) is isolated as a PCR product using two primers (see SEQ ID NOs 17 and 18) with the plasmid pTM4 as template (Munder et al., Mol. Cell. Biol. (1992), 12, 2091-2099).
  • the Xbal-Bglll fragment is subcloned in pUC19Bgl.
  • the insert is confirmed by sequencing (see Example 1 ) and it contains two extra nucieotides after the last complete codon at the 3' end of the gene fragment (see SEQ ID NO 18).
  • the plasmid with the correct insert is named pUC19Bgl/Xbal-Bglll/ACEc_3.
  • the -670 bp Sall-EcoRI fragment from pRH2 and the -304 bp Xbal-Bglll fragment from pUC19Bgl Xbal-Bglll/ACEc_3 are subcloned in pUC19Bgl completely digested with Sail and Bglll. Correct clones are confirmed by appropriate restriction enzyme digests. One such clone is referred to as pRHIOC.
  • Example 6 Construction of yeast expression vectors for the expression of ACE1 C- vKAID) and ACE1C-v2(AID): y1 (AID) and y2(AID) encode the autoinhibitory peptides of the yeast calcineurin catalytic subunits yCNA1 and yCNA2.
  • the -1075 bp Sall-Bglll fragment from pRHIOC (see Example 5), the Bglll-Xbal fragment from either pUC19Bgl/Bglll-Xbal/y1(AID) or pUC19Bgl/Bglll-Xbal/y2(AID) (see Example 3) and the -300 bp Xbal-Sacl fragment from ⁇ UC19/Xbal-Sacl/SUC2t (see Example 4) are ligated to the vector pDP34 which has been completely digested with Sail and Sad.
  • the plasmid pDP34 is an E. coli-S. cerevisiae shuttle vector, which contains the complete S.
  • cerevisiae 2-micron plasmid and encodes the S. cerevisiae URA3 and dLEU2 genes as yeast selection markers (Meyhack et al., in Hershberger-CL; Queener-SW; Hegeman-G (ed.), Genetics and molecular biology of industrial microorganisms, 1989, p. 311-321. American Society for Microbiology, Washington, DC).
  • yeast selection markers Meyhack et al., in Hershberger-CL; Queener-SW; Hegeman-G (ed.), Genetics and molecular biology of industrial microorganisms, 1989, p. 311-321. American Society for Microbiology, Washington, DC.
  • DNA is prepared from 12 transformants. Analyses with Sall/Sacl and BamHI-Sacl confirm the correct clones. Two such clones are referred to as pMH10 [encoding y1 (AID)] and pCS100 [encoding y2(AID)
  • a control plasmid which contains only NLS-ACE1C under the control of the GAPCLp, is prepared by ligating the -1075 bp Sall-Bglll fragment from pRHIOC (see Example 5) and the -300 bp Bglll-Sacl fragment from pUC19/Bglll-Sacl/SUC2t (see Example 4) to the vector pDP34 which has been completely digested with Sail and Sad.
  • the plasmid is named pRH C (Fig. 1).
  • Example 7 Construction of a yeast expression vector for the expression of ACE1C-- vKAIDHGIv..rVl (AID) and ACE1C-v2.AIDHGIv),.-v2(AID), encoding a fusion between the transcription-activation domain ACE1 C and duplicate fragments of the autoinhibitory domains of yCNA1 and vCNA2
  • the -1075 bp Sall-Bglll fragment from pRHIOC (see Example 5) and the Bglll-Xbal fragments from either pUC19Bgl Bglll-Xbal/y1 (AID) or pUC19Bgl/Bglll-Xbal/y2(AID) (see Example 3) are ligated to pUC19 which has been completely digested with Sail and Xbal.
  • the two correct clones are named pUC19/Sall-Xbal/GAPFLp-NLS-ACE1C-y1(AID) or pUC19/Sall-Xbal/G APFLp-NLS-ACEI C-y2(AID).
  • Unphosphorylated linkers (encoding a stretch of four glycines) with SEQ ID NO 19 are ligated to Xbal digested pUC19/Sall-Xbal/GAPFLp-NLS-ACE1C-y1(AID) or pUC19/Sall- Xbal/GAPFLp-NLS-ACE1C-y2(AID).
  • the ligated molecules are isolated on a 1% agarose/Tris-acetate gel.
  • the fragments are isolated, purified by GeneClean (Bio 101 , CA, USA) and re-annealed by incubating at 95°C followed by slow cooling to room temperature.
  • the DNA obtained from HB101 transformants are analyzed on a 2% agarose gel.
  • the clones which show a distinct increase in the molecular size of the Bglll-Xbal fragments from the ones obtained from the starting plasmids are named pUC19/Sall-Xbal/GAPFLp-NLS-ACE1C-y1(AID)-(Gly) 4 and pUC19/Sall-Xbal/ GAPFLp-NLS- ACE1C-y2(AID)-(Gly) 4 .
  • a second copy of y1(AID) is isolated as a Spel-Hindlll fragment by PCR, using the primers in SEQ ID NOs 20 and 21 and the plasmid pUC19/Sall-Xbal/ GAPFLp-NLS-ACE1C-y1(AID) as template. This is subcloned along with a Hindlll-Sacl yeast PH05 transcriptional terminator fragment in pBluescriptKS+. One correct clone is referred to as pBluescriptKS+/Spel-Sacl/y1(AID)-PH05t.
  • a second copy of y2(AID) is isolated as a Spel-Sacl fragment by PCR, using the primers in SEQ ID NOs 22 and 12 and the plasmid pCS100 (see Example 6) as template. This is subcloned in pBluescriptKS+.
  • One correct clone is referred to as pBluescriptKS+/Spel- Sacl/y2(AID)-SUC2t.
  • the -1100 bp Sall-Xbal fragment from pUC19/Sall-Xbal/GAPFLp-NLS-ACE1C-y1(AID) ⁇ (Gly) 4 and the Spel-Sacl fragment from pBluescriptKS+/Spel-Sacl/y1(AID)-PH05t are ligated to the vector pDP34 which has been completely digested with Sail and Sad. After transformation in E. coli HB101 , DNA is prepared from 12 transformants. Analyses with Sall/SacI and BamHI-Sacl confirm the correct clones. One such clone is referred to as pMH11 (encoding two copies of y1 (AID) linked by a glycine linker).
  • the -1100 bp Sall-Xbal fragment from pUC19/Sall-Xbal/GAPFLp-NLS-ACE1C-y2(AID)- (Gly) 4 and the Spel-Sacl fragment from pBluescriptKS+/Spel-Sacl/y2(AID)-SUC2t are ligated to the vector pDP34 which has been completely digested with Sail and Sacl.
  • analyses with Sall/SacI and BamHI-Sacl confirm the correct clones.
  • One such clone is referred to as pCS101 (encoding two copies of y2(AID) linked by a glycine linker).
  • Example 8 Construction of hCNRA2 and hCNRA2 ⁇ . the complete and truncated genes encoding the catalytic subunit of human calcineurin
  • the 3' end ( ⁇ 1280bp) of the human gene (Guerini et al., Proc. Natl. Acad. Sci. USA (1989) 86, 9183-9187) is isolated as two fragments (a -563 bp Ncol-Sacl fragment and a -713 bp Sacl-EcoRI fragment) from human fetal brain cDNA library (Stratagene) by PCR, using two pairs of primers with SEQ ID NOs 23, 24 and 25, 26.
  • the -300 bp 5' end (a Bglll-Ncol fragment) of hCNRA2 is constructed with two overlapping deoxyoligoribonucleotides (which are chemically synthesized using yeast-biased codons; see SEQ ID NOs 27 and 28).
  • primer extension is performed which is followed by a PCR with primers (see SEQ ID NOs 29 and 30; which code for the sense and the anti- sense strand of the 5' and 3' ends of the -300 bp fragment).
  • the Bglll-Ncol fragment is subcloned in pUC19bg_nc (see above; this Example).
  • Six individual clones with -300 bp inserts are sequenced (using the Applied Biosystems DNA sequencer 370A).
  • One correct clone is named pUC19bg_nc/Bglll-Ncol/5'hCNRA2.
  • the complete hCNRA2 gene is assembled from the chemically synthesized -300 bp Bglll- Ncol fragment and the -1280 bp Ncol-EcoRI fragment by subcloning in pUC18Bgl (constructed in the way pUC19Bgl is made; Example 1).
  • Six individual clones are analyzed by restriction enzyme digests. One correct cloned is named pK010.
  • the complete hCNRA2 gene (but lacking the DNA encoding the 2 amino acids at the N-terminus, Met 1 , Ala 2 ) is isolated as a Bglll-EcoRI fragment by PCR, using primers with SEQ ID NOs 31 and 32 and pKO10 as template.
  • the gene encoding the C-terminal truncated version of hCNRA2 i.e. hCNRA2 ⁇
  • hCNRA2 ⁇ which lacks the autoinhibitory domain (and also the DNA encoding the N-terminal residues, Met 1 , Ala 2 ) is isolated as a Bglll-EcoRI fragment by PCR, using primers with SEQ ID NOs 31 and 33 and pK010 as template.
  • Example 9 Construction of two yeast expression vectors for the expression of ACE1C- h(AID) and ACE1C-h(AIDHGIv) 4 -h(AIDV.
  • h(AID) encodes the autoinhibitory peptide of the human brain calcineurin catalytic subunit hCNRA2
  • the second copy of h(AID) is isolated as a Spel-Sacl fragment using the primers with SEQ ID NOs 36 and 12 and pCS102 as template (similar to Example 7).
  • the expression plasmid for ACE1C-h(AID)-(Gly) 4 -h(AID) in pDP34 is constructed in an identical manner to that of pCS101 (see Example 7).
  • the plasmid is named pCS103.
  • Example 10 Construction of pRH1, the vector for expression of fusion genes between the DNA-binding domain of ACE1 (i.e. ACE1 N) and a gene of interest
  • the plasmid pTM9 (Munder et al., Mol. Cell. Biol. (1992), 12, 2091-2099) is digested with EcoRI and Kpnl.
  • the -4400 bp fragment is isolated on a 1% agarose gel and purified by GeneClean ® .
  • a -300 bp EcoRI-Kpnl fragment from pUC19/EcoRI-Kpnl/SUC2t (see Example 4) is ligated to the -4400 bp linearized fragment and transformed in E. coli. Analysis of transformants with EcoRI and Kpnl yielded a plasmid where the CYC1 terminator in pTM9 is replaced by the SUC2 terminator fragment.
  • This plasmid is named pRH1 (Fig. 2) and is a vector which can be used for integration of any gene which is fused to ACE1 N (the DNA-binding domain of the yeast transcription factor ACE1) into the yeast chromosome.
  • Example 11 Construction of veast expression vectors for the expression of ACE1N- vCNA1-PHQ5t. ACE1 N-vCNA2-PHQ5t, ACE1 N-vCNA1 ⁇ -PHQ5t. ACE1 N- yCNA2 ⁇ -PHQ5t, ACE1 N-hCNRA2-SUC2t and ACE1 N-hCNRA2 ⁇ -SUC2t in PRH1
  • ACE1N-yCNA1-PH05t The subcloning of ACE1N-yCNA1-PH05t, ACE1N-yCNA2-PH05t, ACE1N-yCNA1 ⁇ -PH05t and ACE1 N-yCNA2 ⁇ -PH05t in pRH1 is performed in an identical manner.
  • a Bglll-Hindlll fragment containing the complete yCNA1 or yCNA2 genes (or their truncated versions; Examples 1 and 2) and the Hindlll-Kpnl fragment of the yeast PH05 transcription terminator are ligated to pRH1 (see Example 10) which is completely digested with Bglll and Kpnl. Restriction enzyme analysis of DNA, obtained from E.
  • the plasmids are named pMH6, pMH7 (encoding ACE1N-yCNA1 and ACE1N- yCNAI ⁇ , respectively) and pMH21, pMH22 (encoding ACE1N-yCNA2 and ACE1 N-yCNA2 ⁇ , respectively)
  • the Bglll-EcoRI fragments containing the hCNRA2 and hCNRA2 ⁇ genes are subcloned directly in Bglll-EcoRI digested pRH1.
  • the plasmids are named pK011 , pK012 (encoding the ACE1 N-hCNRA2 and ACE1 N-hCNRA2 ⁇ fusions, respectively).
  • Example 12 Construction of a veast vector for expression of vTPK1. the complete gene encoding the catalytic subunit of veast cAMP-dependent protein kinase
  • a -1200 bp Bglll-EcoRI fragment of the yTPK1 gene (the complete coding sequence; Toda et al., Cell (1987), 50, 277-287) is isolated from the yeast genome by PCR using the primers with SEQ ID NOs 37 and 38.
  • the -1200 bp Bglll-EcoRI fragment of yTPK1 is subcloned in pRH1 (see Example 10).
  • One clone, which contains the correct insert (confirmed by restriction enzyme analysis and DNA sequencing) is named pSK1 A.
  • Example 13 Construction of a veast expression vector for expression of the regulatory subunit of yTPK1 , i.e. yBCYI : the complete gene which also encodes the inhibitory peptide of yTPK1
  • a -1260 bp BamHI-EcoRI fragment of the yeast BCY1 gene (the complete coding sequence, Toda et al., Mol. Cell. Biol. (1987), 7, 1371-1377) is isolated from the yeast genome by PCR, using the primers with SEQ ID NOs 39 and 40.
  • yBCYI As a ACE1C-yBCY1 fusion, the -1075 bp Sall-Bglll fragment from pRHIOC (see Example 5), the -1260 bp BamHI-EcoRI fragment of the yeast BCY1 gene and the -300 bp EcoRI-Sacl fragment from pUC19/EcoRI-Sacl/SUC2t (see Example 4) are ligated to the vector pDP34 which has been completely digested with Sail and Sad.
  • pSK5 One clone, which contains the correct insert (confirmed by restriction enzyme analysis and DNA sequencing) is named pSK5.
  • Example 14 Construction of veast expression vectors for the expression of ACE1C- BCYKwt ID) ACE1 C-BCY1 (Mut1 ID) and ACE1 C-BCY1 (Mut2 ID) which encode a single copy of the gene fragments encoding the inhibitory peptide (ID) of veast BCY1 (wild type, pseudosubstrate and a mutated pseudosubstrate)
  • the resulting correct clones are named pUC19/Sall-Xbal/GAPCLp- ACE1C-BCY1 (wt-ID), pUC19/Sall-Xbal/GAPCLp-ACE1C-BCY1 (Mut1 -ID) and pUC19/Sall- Xbal/GAPCLp-ACE1 C-BCY1 (Mut2-ID).
  • the individual Sall-Xbal fragments from the above plasmids and a Xbal-Sacl fragment from pUC19/Xbal-Sacl/SUC2t are subcloned in pDP34 (as described in Example 6).
  • the expression plasmids are named pSK26, pSK21 and pSK22 [encoding ACE1C- BCYI(wt-ID)], pSK21 [encoding ACE1C-BCY1(Mut1-ID)] and pSK22 [encoding ACE1C- BCY1 (Mut2-ID)].
  • Example 15 Construction of veast expression vectors for the expression of ACE1 C- BCYKMut/l ID)-(Glv) 4 -BCY1 (Mut1 ID) and ACE1C-BCY1 (Mut2 ID)-(Glv) 4 - BCY1(Mut2 ID), the gene fragments encoding the inhibitory peptides of veast BCY1 (pseudosubstrate and a mutated pseudosubstrate): two copies linked by qlycine linkers
  • BCYI(wt-ID), BCY1(Mut1-ID) and BCY1 (Mut2-ID) are isolated by PCR using the primers (SEQ ID NOs 44 and 45), the templates being pSK26, pSK21 and pSK22, respectively.
  • Expression plasmids in pDP34 are made as described in Example 7.
  • Example 16 Isolation of the three fragments from human p70 s6 kinase (p70s6k). the complete gene, a C-terminal truncated version of p70s6k (p70s6k ⁇ C) and an N-terminal truncated version of p70s6k (p70s6k ⁇ N), for expression as fusion genes with ACE1 N
  • PCR is performed on the cDNA encoding the mitogen-activated S6 kinase (i.e. p70s6k) obtained from the rat liver (Kozma et al., Proc. Natl. Acad. Sci. USA (1990), 87, 7365-7369).
  • the rat gene encodes a polypeptide identical to the human protein.
  • Three pairs of deoxyoligoribo ⁇ nucleotides are used as primers (see SEQ ID NOs 45 and 46; 45 and 47 and 48 and 46).
  • the genes, obtained as BamHI-Xbal/ BamHI-EcoRI fragments, are subcloned in pRH1 (see Example 10).
  • the resulting plasmids are named pSK18 (encoding wild type (wt) p70s6k), pSK6 (encoding p70s6k ⁇ C) and pSK27 (encoding p70s6k ⁇ N), respectively.
  • Example 17 Construction of veast expression vedors for the expression of ACE1C-s6k(wt AID), ACE1C-s6k(Mut1-AID) and ACE1C-s6k(Mut2-AID): single copies of the gene fragments encoding the autoinhibitory peptides of human p70 s6 kinase (wild type, pseudosubstrate and a mutated pseudosubstrate)
  • the Bglll-EcoRI -312 bp fragments containing the wild type or mutated autoinhibitory peptide sequences (Banerjee, et al., Proc. Natl. Acad. Sci. USA (1990), 87, 8550-8554) are subcloned in the context of the activation domain of the yeast transcriptional activator ACE1 in the expression vector pDP34 (as in Example 6).
  • the pair of deoxyoligoribonucleotides with SEQ ID NOs 49 and 46 are used to isolate the wild type (wt) and the two mutated sequences as Bglll-EcoRI fragments.
  • the resulting plasmids are named pSK11 (wt), pSK13 (Mut1 ) and pSK12 (Mut2).
  • a Bglll-EcoRI -513 bp fragment (comprising the above -312 bp fragment and a 5' extension of -200 bp) is subcloned by PCR from the wt gene and the mutated sequences, which encode the Mut1-AID and Mut2-AID mutations.
  • the pair of deoxyoligoribonucleotides with SEQ ID NOs 50 and 46 are used to isolate the wt and the two mutated sequences as Bglll- EcoRI fragments. They are cloned as ACE1C fusions in pDP34, as detailed in Example 6. They are referred to as pSK8 (wt), pSK10 (Mut1) and pSK9 (Mut2).
  • Example 18 Construction of plasmids for the expression of p70s6k. p70s6k ⁇ C and p70s6k ⁇ N from veast multi-copy vectors
  • a -670 bp Sall-Bglll fragment (containing the GAPCL promoter) is isolated from pRH2 (see Example 5) by PCR using the primers with the SEQ ID NOs 51 and 52.
  • the above Sall-Bglll fragment, the BamHI-Xbal/ BamHI-EcoRI fragments (encoding the sequences of p70s6k, p70s6k ⁇ C and p70s6k ⁇ N; see Example 16) and a Xbal-Sacl/ EcoRI- Sacl fragment of the SUC2 terminator (see Example 4) are subcloned in pDP34 digested completely with Sail and Sad.
  • the correct clones are named pSK16 (encoding p70s6k), pSK18 (encoding p70s6k ⁇ C) and pSK28 (encoding p70s6k ⁇ N).
  • yeast transformants of pSK16 yield an active protein. No protein is seen in cells harboring pSK18 and pSK28. However, the amount of mRNA obtained from the latter is the same as in cells expressing full length p70S6k.
  • Example 19 Chromosomal integration of ACE1 N fusion genes in the veast strain TFY2
  • the Bio-Rad gene pulser is employed for transformation of yeast cells (see Table 1) by electroporation (Methods. Enzymol. (1991), 194, 182-187).
  • the strain TFY2 (Mat ⁇ his ura3- 52 tro1-285 acel LEU2::YipCL CUP1) (Munder et al., Mol. Cell. Biol. (1992), 12, 2091-2099) is used for all integrations of ACE1N-gene fusions into the yeast chromosome. Correct gene integration and gene replacement events are verified by PCR with primers flanking the insertion sites. Subsequently, the amplified fragments are analyzed by agarose gel electrophoresis.
  • Example 20 Yeast transformations with plasmids. in strains harboring gene fusions with ACE1N
  • Yeast strains harboring ACE1N gene fusions are transformed with plasmids bearing the different ACE1C fusions as described in Example 19. The transformants are depicted in Table 2.
  • Example 21 Assay for copper resistance: induction of metallothionein expression
  • Equal numbers of cells are spotted onto SD-agar plates (2 % glucose, 0.67 % yeast nitrogen base without amino acids, 2 % agar) containing (a) no CuS0 4) (b) 100 ⁇ M CuS0 4 and (c) 200 ⁇ M CuS0 4 (Munder et al., Mol. Cell. Biol. (1992), 12, 2091-2099).
  • the results are portrayed in Table 2.
  • Yeast cells (Example 19) are grown in YPD medium (1 % bacto-yeast extract, 2 % bacto- peptone, 2 % glucose) for 17 h at 30°C. Cells are first washed in SD medium (0.67 % yeast nitrogen base without amino acids, 2 % glucose) and then the transcription of the reporter gene is induced. Induction and permeabilization of cells are performed as described previously (F ⁇ rst et al., Cell (1988), 55, 705-717). ⁇ -galactosidase activity, measured as o-nitrophenyl- ⁇ -D-galacto-pyranoside hydrolysis at 420 nm, is normalized to cell culture density and expressed as arbitrary units. The activity in the control strains, harboring the plasmid pRH14C, is set to the value 1. The results are portrayed in Table 2.
  • Cells are initially grown in YPD, as in Example 22. After washing in SD, cells are preincubated with small organic compounds (dissolved in dimethyl sulphoxide and 10-20 ⁇ molar in final concentration) for 90 min at 30°C. Later, ⁇ -galactosidase activity is measured, exactly as in Example 22.
  • Example 24 Disruption of protein-peptide interaction in CNY15 with the immunosuppressants cyclosporin A and FK506
  • Example 22 ⁇ -galactosidase activity is measured, as in Example 22.
  • three individual transformants from CNY16 see Table 2 are used.
  • the results, an average of three transformants (in duplicate), are depicted in Table 3.
  • the units shown are arbitrary (see Example 22).
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • FEATURE FEATURE
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)

Abstract

Described is a dual-hybrid approach for the determination of interactions between a phosphatase or a kinase and polypeptides that bind to these enzymes like autoinhibitory domains. Using the inventive approach it is possible to measure the influence of antagonists and agonists and, hence, to design regulatory polypeptides with increased regulatory properties.

Description

DUAL HYBRID SYSTEM
Phosphatases and kinases are enzymes that are generally involved in the regulation of enzyme activity by adding or removing of phosphate groups to enzymes. The activity of these enzymes is often regulated by the binding of another protein and/or by an autoinhibitory domain. This binding of the autoinhibitory domain again is regulated, e.g., by a peptidic or non-peptidic compound that binds to the autoinhibitory domain.
A protein phosphatase of the 2B subfamily, one of four classes of phosphoserine/ phospho- threonine-specific phosphoprotein phosphatases that have been distinguished on the basis of their sensitivities to inhibitors and divalent cations, is calcineurin. Calcineurin is the only known phosphatase that is regulated specifically by Ca2+ and calmodulin. The calcineurin holoenzyme purified from mammalian cells (Guerini et al., Proc. Natl. Acad. Sci. USA (1989), 86, 9183-9187) is a heterodimer consisting of a large catalytic subunit (51-61kD) and a small regulatory subunit (~19kD). The catalytic subunit binds calmodulin, and the regulatory subunit attaches up to four molecules of Ca2+. The catalytic activity of the calcineurin holoenzyme is completely inhibited by a synthetic peptide corresponding to a region in the C-terminus of the catalytic subunit in the presence of Ca +-calmodu!in. This suggests that the catalytic subunit contains an autoinhibitory domain (AID) (Hashimoto et al., J. Biol. Chem. (1990), 265, 1924-1927).
The budding yeast Saccharomyces cerevisiae contains proteins with properties similar to the mammalian catalytic and regulatory subunits of calcineurin. In fact, yeast cells possess two genes, CNA1 and CNA2, which encode for the mammalian catalytic subunit (Cyert et al., Proc. Natl. Acad. Sci. USA (1991), 88, 7376-7380). Both the Cna1 and Cna2 proteins contain regions which have similarity to the putative AID sequence of the mammalian enzyme (Hashimoto etai, J. Biol. Chem. (1990), 265, 1924-1927).
Recent findings indicate that two drug-protein complexes, cyclosporin A-cyclophilin and FK506-FKBP, probably bind to the same target, calcineurin (Schreiber, Cell (1992), 70, 365- 368). Cyclosporin A (CsA) is an undecapeptide (Schreiber, Science (1991 ), 251 , 283-287) and acts as an inhibitor of T-cell activation. It is currently the favored therapeutic agent for prevention of graft rejection after organ and bone marrow transplantation. CsA binds to family of conserved proteins, named cyclophilins, having high affinity for CsA (Schreiber, Science (1991), 251 , 283-287).
More recently, the new compound FK506 (a macrolide; Liu, Immunol. Today (1993), 14, 290-295) has been discovered that also inhibits T-cell activation. For FK506 it has been shown that this compound binds to a separate group of conserved proteins (Schreiber, Science (1991), 251, 283-287), which have been termed the FK-binding proteins (FKBPs).
An example for a cAMP dependent protein kinase is PKA. This enzyme is a member of the large group of eukaryotic protein kinases that play critical roles in regulation of cell growth and comprises a catalytic and a regulatory subunit. PKA in its inactive state consists of a tetramer consisting of two identical catalytic and two identical regulatory subunits. This enzyme is activated, like the other protein kinases, by dissociation of the regulatory and the catalytic subunit to form a dimer of active catalytic subunits. This dissociation is mediated, e.g., by cAMP.
Another example for a kinase is p70S6, a single chain enzyme involved in the regulation of protein synthesis. The target for p70S6 is the 40S ribosomal protein S6. It is supposed that phosphorylation of S6 either triggers or facilitates the activation of protein synthesis. p70S6 is supposed to be regulated by an autoinhibitory domain at the C-terminus (Flotow et al., J. Biol. Chem., (1992), 267, 3074-3078) and through serine/threonine phosphorylation by insulin/mitogen-activated protein kinases.
A new approach for the detection of protein-protein interaction, as for example, crucial in the regulation of protein phosphatases or kinases is the two-hybrid system (Fields et al., Nature (1989), 340, 245-246). This system provides a convenient method in which the possible interactions between a peptide and a protein can be examined in a cellular environment. The system depends on the reconstitution of a transcription factor from its two essential components, the DNA-binding domain and its activating sequence. In particular, two fusion proteins are generated, each comprising one of the two domains of the transcription factor and one of the two proteins that are being tested for their ability to bind to each other. Only when the proteins to be tested interact, a functional transcription reconstitutes. Depending on the strength of the protein-protein interactions, the activation of gene transcription varies. To monitor the formation of a functional transcription factor, the expression of the gene triggered by said reconstituted transcription factor is measured.
Summary of the Invention
Suφrisingly, it has now been found, that this dual-hybrid approach is capable of determining the interaction between a phosphatase or a kinase and its autoinhibitory domain (AID). Using the inventive approach it is suφrisingly possible to measure the influence of antagonists and agonists and, hence, to find new regulatory polypeptides and to design regulatory polypeptides with increased regulatory properties. It has been suφrisingly found, for example, that cyclosporin A and FK506 despite their different structure inhibit the formation of active-center-AID-complex. Using the inventive method it is suφrisingly possible to identify new agonists or antagonists of a phosphatase or a kinase. Additionally, it has been found suφrisingly that autoinhibitory domains exhibit better binding properties when present in several copies.
Detailed description of the invention
The current invention concems a transcription system for measuring the interaction between a phosphatase or kinase, or a mutein or fragment thereof that binds an autoinhibitory domain, with said autoinhibitory domain, comprising a) the DNA binding domain of a transcription factor and the transcription activation domain of a transcription factor that are separated, wherein one of the two transcription factor domains is linked to a polypeptide comprising a phosphatase or kinase or a fragment thereof that binds an autoinhibitory domain; and the other of the two transcription factor domains is linked to a polypeptide comprising an autoinhibitory domain that is capable of binding to the polypeptide linked to the first transcription factor domain, and b) a DNA that is transcribed when the DNA binding domain of said transcription factor and the transcription activation domain of said transcription factor are connected via the polypeptides linked thereto. Using the inventive system it is possible to measure all parameters that influence the binding of the autoinhibitory domain to its target region on the regulated enzyme.
A preferred phosphatase or kinase comprises an autoinhibitory domain (AID) that can be located on the catalytic or a regulatory subunit. Examples for a phosphatase or kinase are phosphatase A1 and A2B, cyclic GMP dependent kinase (cGPK), myosin light chain kinase (MLCK), myosin heavy chain kinase, dsRNA-dependent kinase, dsDNA-dependent kinase, protease activated kinase I and II, cell cycle kinase cdc-28 MPF, growth factor regulated kinase, mammary gland casein kinase, glycogen synthase kinase-3, AMP activated protein kinase, pyruvate dehydrogenase kinase, branched chain α-ketoacid dehydogenase kinase, endogenous elF-4E kinase, histone H4 kinase I and II, isocitrate dehydrogenase kinase, β- adrenergic receptor kinase, rhodopsin kinase, tropomyosin kinase, proline-dependent protein kinase, calmodulin dependent kinase All and III, phosphokinase, casein kinase Al and II, pp60, the family of src kinases, the family of cyclin-dependent kinases (cdk-s), EGF receptor, insulin receptor, spleen tyrosine kinase, protein kinase C, calcineurin, PKA and p70S6 kinase. More preferred are calcineurin, PKA and p70S6 kinase.
In the inventive system it is advantageous to use a form of said phosphatase or kinase or a mutein or fragment of said phosphatase or kinase that has a free AID binding domain. In this form the AID that is part of the original enzyme is not bound to the catalytic domain. This form can be achieved via phosphorylation, lack of certain deactivating factors, addition of activation factors or via a mutein that does not comprise a functional AID. The AID can be inactivated using several approaches. It is, for example, possible to delete the AID on DNA-level, to alter the AID by mutagenesis to be inactive or to use only a fragment of the protein that does not comprise the AID. Nevertheless, it is important that the mutein is not changed to such an extent that the autoinhibitory domain used in the dual hybrid test cannot bind anymore. It is, for example, possible to use a fragment of calcineurin that lacks the C-terminal AID, especially the C-terminal 40-60 amino acids.
Autoinhibitory domains that interact with or bind to a phosphatase or kinase are well known in the art. The interaction of these autoinhibitory domains and the corresponding enzymes by formation of a complex is sensitive to various parameters like compounds that compete with the autoinhibitory domain for the same attachment site, compounds that change the affinity of the autoinhibitory domain for the attachment site or compounds that change the affinity of the attachment site for the autoinhibitory domain. These compounds can be, for example, peptides, chemical compounds, metal salts or compounds comprising peptidic and non-peptidic parts. Examples for known regulatory compounds are DNA, RNA, steroids, macrolides, cAMP, cGMP, calmodulin, phosphatidyl serine, diacyl glycerol, insulin, epidermal growth factor, interleukins, cytokines, growth factors like IGF and GMCSF, and Ca2\ Preferred examples for such autoinhibitory domains are the inhibitory or auto¬ inhibitory domains of the catalytic or regulatory subunit of a phosphatase or kinase (Kemp et al., Trends in Biochem. Sci. (1990), 15, 342-346), e.g. of the regulatory subunit of PKA and the AID of calcineurin or p70S6 and fragments thereof that are still capable of binding to the phosphatase or kinase in question. In a more preferred embodiment of the invention the autoinhibitory domain and the fragment that binds an autoinhibitory domain originate from the same enzyme komplex. In an even more preferred embodiment of the invention the autoinhibitory domain and the fragment that binds an autoinhibitory domain originate from the same enzyme. Also included are artificial substrates or pseudosubstrates of the phosphatase or kinase to be tested.
Pseudosubstrates are, for example, created by replacing amino acids of natural occurring autoinhibitory domains with amino acids that promote binding to the enzyme. Examples are the replacement of one or more serine, threonine and/or thyrosine by another amino acid like alanine (Hardie, Nature (1988), 335, 592-593).
A preferred polypeptide that binds to the phosphatase or kinase as described above is a polypeptide comprising the regulatory subunit of PKA, the autoinhibitory domain of calcineurin and or p70S6 kinase, as well as fragments thereof capable of binding to enzyme in the test. Especially preferred are the regulatory subunit of PKA, a fragment of calcineurin comprising the C-terminal 40 to 60 amino acid and a fragment of p70S6 kinase comprising amino acid 332 to 502 or 399 to 502.
Additionally, the autoinhibitory domain can be linked to the transcription factor domain as a single copy or in several copies which is preferred, e.g., 1 to 5 copies of the AID or 2 to 4 copies which is preferred. It is also possible to link different autoinhibitory domains to the same transcription factor to test, e.g., different influences. The different autoinhibitory domains or the copies of the same autoinhibitory domain may be connected directly or with spacer groups. Spacer groups are, for example, α-helix breakers like short peptides of repeated amino acids like Gly3, Gly4 or Gly5.
Transcription factors according to the invention are proteins that bind to a certain region of DNA (promoter) and initiate the transcription of a DNA sequence that belongs to it. These transcription factors usually comprise a domain that is responsible for the DNA recognition or binding and a domain that initiates transcription. DNA recognition and transcription initiation domains are known for several transcription factors such as Ace1 , Gal4, VP16, p53 and lexA.
For the inventive system the two domains necessary for transcription initiation of a certain gene can originate from two different transcription factors or from the same transcription factor. For example, both domains may originate form the CUP1 or Gal4 transcription factor or the DNA binding domain originates from the lexA transcription factor and the transcription activating domain originates from the VP16 or p53 transcription factor; or any other combination thereof.
For example, in the case of Ace1 , a transcription factor for the initiation of the transcription of metallothioneins (CUP1), the DNA binding domain is located in the region comprising N-terminal amino acids, preferred are the N-terminal 122 amino acids, and the transcription activation domain is located in the region comprising C-terminal amino acids, wherein the C-terminal 100 amino acids are preferred, (Cizewski et al., Proc. Natl. Acad. Sci. USA (1988), 86, 8377-8381).
According to the invention, one of the two transcription factor domains is linked to a polypeptide comprising a phosphatase or kinase or a fragment thereof that binds an autoinhibitory domain, as described above. The other of the two transcription factor domains is linked to a polypeptide comprising an autoinhibitory domain that is capable of binding to the phosphatase or kinase linked to the first transcription factor domain, as described above.
These autoinhibitory domains can be linked to one of the transcription factor domains, as defined above, directly or via a spacer, in frame. A further aspect of the invention is an expression cassette for the expression of a fusion protein comprising the DNA binding domain or the transcription activation domain of a transcription factor and a polypeptide comprising a phosphatase or kinase or a fragment thereof that binds an autoinhibitory domain; or a polypeptide comprising said autoinhibitory domain or an active fragment thereof that is capable of binding to said phosphatase or kinase or a fragment thereof.
Methods for the construction of an expression cassette comprising a DNA coding for a fusion protein comprising one of the two transcription factor domains and one of said polypeptides are known in the art and are described for example in Fields et al., Nature (1989), 340, 245-246; Chien etal., Proc. Natl. Acad. Sci. USA (1991), 88, 9578-9582; Yang etal., Science (1993), 257, 680-682.
Another aspect of the current invention is a DNA that is transcribed when the DNA binding domain of a transcription factor and the transcription activation domain of a transcription factor are joined via the polypeptides linked thereto, as described above, if this DNA is not already part of the natural genome of the host that is used for the test. This DNA is usually comprised in an expression cassette comprising a promoter that is operably linked to said DNA and to a sequence containing a transcription termination signal, as described above. In a preferred embodiment of the invention said DNA is coding for a polypeptide.
The promoter of the expression cassette is chosen in accordance with the transcription factor fragment used. For example, suitable transcription factor/promoter combinations are Ace1/CUP1p or Gal4/Gal1-Gal10p (Chien et al., Proc. Natl. Acad. Sci. USA (1991), 88, 9578-9582; Yang et al., Science (1993), 257, 680-682). In a preferred embodiment of the present invention the promoter is the CUP1 promoter.
A suitable DNA that is transcribed under the control of this promoter usually causes an effect that can be measured easily during or after transcription or translation. Preferred are transcription or translation products that can be measured easily e.g. via the measurement of the amount of protein, mRNA or DNA produced; or that cause an effect that can be measured easily, e.g. cell growth, an enzymatic reaction or color. Hence, the transcribed DNA codes, for example, for a protein that is produced in an amount that is related to the amount of activation of said promoter and that is, e.g., not produced elsewhere in the chosen microbiological host under the applied conditions. Examples for suitable proteins are the metallothionein that is encoded by the yeast CUP1 gene, β-galactosidase or luciferase. Preferred is metallothionein and β-galactosidase.
An expression cassette for said suitable DNA may be already present in the microbiological host. In this case, the corresponding original transcription factor is inactivated or replaced by the inventive transcription factor fusion constructs. Hence, the reconstitution of the promoter will induce the transcription of a genuine gene, that is, e.g., necessary for survival of the microbiological host under the condition applied. An example is the replacement of the original Ace1 domain(s) with the separated Ace1 domain(s) modified according to the invention, resulting in a yeast whose sensitivity to Cu + depends on the reconstitution of the functional Ace1. A microbiological host transformed with this inventive system will, for example, grow in Cu2+ containing media only if the two transcription factor domains are linked via the associated phosphatase or kinase, as defined above, and the associated autoinhibitory domain of this phosphatase or kinase, as defined above.
In the expression cassettes of the present invention, the promoter is operably linked to the encoded protein. Additional sequences, such as pro- or spacer-sequences which may or may not carry specific processing signals can also be included in the constructions to facilitate accurate processing of precursor molecules. Altematively fused proteins can be generated containing internal processing signals which allow proper maturation in vivo or in vitro.
Preferably, the expression cassettes according to the present invention comprise also the 3'-flanking sequence of a gene which contains the proper signals for transcription termination and polyadenylation. Suitable 3'-flanking sequences are for example those of the gene naturally linked to the promoter used, or 3'-flanking sequences of other yeast genes, e.g., of the PHO5 or the SUC2 gene. An expression cassette comprising the DNA that is transcribed under the control of the inventive transcription factor construct may, for example, contain additionally a DNA sequence encoding a signal peptide. The expression cassettes for the transcription factor fusion proteins and the DNA that is transcribed by the reconstituted transcription factor may be present on different plasmids or some or all together on one plasmid. These plasmids may be integrated into the genome of the microbiological host or may retain as separate units. It is for example possible to integrate the expression cassettes for the modified transcription factor domains into the genome of the microbiological host, e.g. at the position of the original transcription factor domains and inactivating therewith the original factor, as described in (Munder & Fϋrst, Mol. Cell. Biol. (1992), 12, 2091-2099). The expression cassette expressing the polypeptide to be monitored may be inserted, if it is not already part of the genome of the microbiological host, in form of a stable plasmid, e.g., in Saccharomyces cerevisiae in form of a two-micron based plasmid as described in EP-341215.
The hybrid vectors according to the invention are selected from the group consisting of a hybrid plasmid and a linear DNA vector and are further selected depending on the host organism envisaged for transformation.
Accordingly, the invention relates also to hybrid vectors comprising the expression cassettes described above.
Hybrid plasmids that retain as separate units carry the expression cassettes according to the invention and as additional DNA sequences a yeast replication origin and a selective genetic marker for yeast. Hybrid plasmids containing a yeast replication origin, e.g. an autonomously replicating segment (Ars), are extrachromosomally maintained within the yeast cell after transformation and are autonomously replicated upon mitosis. Hybrid plasmids containing sequences homologous to yeast 2μ plasmid DNA can be used as well. These hybrid plasmids will get integrated by recombination into 2μ plasmids already present within the cell or will replicate autonomously. 2μ sequences are especially suitable for high- frequency transformation plasmids and give rise to high copy numbers.
In addition, the preferred hybrid plasmids according to the invention may include a DNA sequence as part of a gene present in the host yeast chromosome (e.g. the gene for the transcription factor domain or its promoter linked to the transcription factor constructs). By virtue of the homologous sequence, which should amount to a stretch of at least 20 to 100 deoxynucleotides, the whole plasmid or linear fragments thereof can be stably incoφorated into the host chromosome by recombination. Thus, during propagation the progeny cells will retain the introduced genetic material even without selective pressure.
As to the selective gene marker for yeast, any marker gene can be used which facilitates the selection for transformants due to the phenotypic expression of the marker. Suitable markers for yeast are particularly those expressing antibiotic resistance or, in the case of auxotrophic yeast mutants, genes which complement host lesions. Corresponding genes confer, for example, resistance to the antibiotic cycloheximide or provide for prototrophy in an auxotrophic yeast mutant, for example the URA3, LEU2. HIS3 or TRP1 gene. It is also possible to employ as markers structural genes which are associated with an autonomously replicating segment providing that the host to be transformed is auxotrophic for the product expressed by the marker.
Advantageously, the additional DNA sequences which are present in the hybrid plasmids according to the invention also include a replication origin and a selective genetic marker for a bacterial host, especially Escherichia coli. There are useful features which are associated with the presence of an E. coli replication origin and an E. coli marker in a yeast hybrid plasmid. Firstly, large amounts of hybrid plasmid DNA can be obtained by growth and amplification in E. coli and, secondly, the construction of hybrid plasmids is conveniently done in E. coli making use of the whole repertoire of cloning technology based on E. coli. E. coli plasmids, such as pBR322 and the like, contain both E. coli replication origin and E. coli genetic markers conferring resistance to antibiotics, for example tetracycline and ampiciilin, and are advantageously employed as part of the yeast hybrid vectors.
The additional DNA sequences which contain, for example, replication origin and genetic markers for yeast and a bacterial host (see above) are hereinafter referred to as "vector DNA" which together with the yeast promoter and the coding region is forming a hybrid plasmid according to the invention. The preferred hybrid vectors of the present invention are prepared by methods known in the art, for example by linking a suitable promoter, a coding region, the 3' flanking sequence of a yeast gene and optionally vector DNA.
For the preparation of hybrid plasmids, conveniently mapped circular vector DNA, for example bacterial plasmid DNA or the like (see above), having at least one restriction site, preferably two or more restriction sites, can be employed. Advantageously, the vector DNA already contains replication origins and gene markers for yeast and/or a bacterial host. The vector DNA is cleaved using an appropriate restriction endonuclease. The restricted DNA is ligated to the DNA fragment containing the yeast promoter and to the DNA segment coding for the desired protein. Prior to or after linking of the promoter and the coding region (or simultaneously as well), it is also possible to introduce replication origins and/or markers for yeast or a bacterial host. At all events, the restriction and ligation conditions are to be chosen in such a manner that there is no interference with the essential functions of the vector DNA and of the promoter. The hybrid vector may be built up sequentially or by ligating two DNA segments comprising all sequences of interest.
Various techniques may be used to join DNA segments in vitro. Blunt ends (fully base- paired DNA duplexes) produced by certain restriction endonucleases may be directly ligated with T4 DNA ligase. More usually, DNA segments are linked through their single-stranded cohesive ends and covalently closed by a DNA ligase, e.g. T4 DNA ligase. Such single- stranded "cohesive termini" may be formed by cleaving DNA with another class of endonucleases which produce staggered ends (the two strands of the DNA duplex are cleaved at different points at a distance of a few nucieotides). Single strands can also be formed by the addition of nucieotides to blunt ends or staggered ends using terminal transferase ("homopolymeric tailing") or by simply chewing back one strand of a blunt- ended DNA segment with a suitable exonuclease, such as I exonuclease. A further approach to the production of staggered ends consists in ligating to the blunt-ended DNA segment a chemically synthesized linker DNA which contains a recognition site for a staggered-end forming endonuclease and digesting the resulting DNA with the respective endonuclease. The components of the hybrid vector according to the invention, such as the yeast promoter, the structural gene optionally including a signal sequence, transcription terminator, the replication system etc., are linked together in a predetermined order to assure proper function. The components are linked through common restriction sites or by means of synthetic linker molecules to assure proper orientation and order of the components.
A linear DNA vector is made by methods known in the art, e.g. linking the above yeast promoter to the coding region in such a manner that the coding region is controlled by said promoter, and providing the resulting DNA with a DNA segment containing transcription termination signals derived from a yeast gene.
Joining of the DNA segments may be done as detailed above, viz. by blunt end ligation, through cohesive termini or through chemically synthesized linker DNAs.
The DNA fragments coding for fragments or domains of polypeptides, e.g., a polypeptide comprising a phosphatase or kinase or a fragment thereof that binds an autoinhibitory domain; a polypeptide comprising said autoinhibitory domain; the DNA binding domain; and the transcription activation domain of a transcription factor, as described above, can be isolated by methods known in the art. It is for example possible to isolate the desired fragment from a gene bank using specific hybridization probes, to synthesize the desired fragment in a DNA synthesizer, to amplify the specific fragment via PCR techniques or to use any combination thereof.
Excision of a portion of a DNA coding for a protein-domain like the transcription activation or the DNA binding domain of a transcription factor, or a phosphatase or kinase lacking the autoinhibitory domain may be effected by using restriction enzymes. A prerequisite of this method is the availability of appropriate restriction sites in the vicinity of the ends of the DNA coding for the desired domain. For convenience and in order to facilitate handling of the protein domain the latter is advantageously contained in a greater DNA segment provided with appropriate linkers which allow insertion and cloning of the segment in a cloning vector. A preferred microbiological host for the constructs described above is a yeast or bacterial cell, wherein yeast is more preferred and Saccharomyces cerevisiae is especially preferred.
The expression cassettes or hybrid vectors described above can be integrated into the microbiological host by standard methods in genetic engineering.
The microbiological host originating therefrom comprises one or more expression cassettes for the two modified transcription factors and one ore more expression cassettes expressing the polypeptide to be monitored.
The transcription system according to the invention or the host transformed therewith can be used for the identification of an agonist or antagonist of a phosphatase or kinase as described above.
In a preferred embodiment of the invention the inventive transcription system can be used to identify an antagonist of the phosphatase or kinase as described above.
Accordingly, a further embodiment of the invention is a method for the identification of a phosphatase or kinase agonist and antagonist comprising a) treating a transformed microbiological host as defined above with a test compound, and b) measuring the amount of transcription activation caused by the two modified transcription factor fragments, e.g. by measuring the amount of a produced mRNA, DNA, protein or by measuring an effect caused by the induced transcription or translation product.
The agonist and antagonist identified using the inventive system have valuable pharmacological properties an can be used in a method of treatment. Indications for these agonists and antagonists are, for example, cancer, arthritis, psoriasis, graft rejection, autoimmune diseases, allergy, Alzheimer's disease and regulation of cell proliferation. It is, for example, possible to use the calcineurin antagonists in a method of treatment that is characterized by inhibiting T-cell activation, especially in a method of treatment or prevention of graft rejection. Also enclosed by the present invention is a pharmaceutical composition comprising one or more of the compounds identified by the inventive system or pharmacologically acceptable salt thereof, optionally together with pharmacologically suitable carrier.
Brief description of the drawings
In the following experimental part various embodiments of the present invention are described with reference to the accompanying drawings in which:
Fig. 1 is a schematic illustration of plasmid pRH1.
Fig. 2 is a schematic illustration of plasmid pRH14C.
Fig. 3 is a schematic illustration of plasmid YipCL.
Fig. 4 is a schematic illustration of plasmid pMH7.
Fig. 5 is a schematic illustration of plasmid pMH10.
The following examples illustrate the invention and should not be construed as a limitation thereof.
Examples
All standard methods in genetic engineering are carried out as described in: Sambrook et al., Molecular Cloning: A laboratory manual, 2nd Edn. 1989,
The enzyme employed for all PCR reactions is Vent polymerase (New England Bio-Labs) The Primers are synthesized on a DNA synthesizer
Example 1 : Isolation of vCNA1 and vCNA2 yCNA1 and yCNA2 are the complete genes from the yeast genome encoding the two isozymes for the catalytic subunit of yeast calcineurin. In order to obtain the yCNA1 and yCNA2 genes for convenient cloning in a yeast expression vector, the polymerase chain reaction (PCR) is performed on yeast genomic DNA (obtained from the wild type strain S288C), using two pairs of deoxyoligoribonucleo- tides as primers (SEQ ID NOs 1 , 2 and 3, 4). The primers correspond to the published sequences of yeast CNA1 and CNA2 (Cyert et al., Proc. Natl. Acad. Sci. USA (1991 ) 88, 7376-7380). The yeast cDNA is amplified in 30 cycles of PCR. The Bglll-Hindlll fragments containing the coding regions of yCNA1 and yCNA2 are ligated to the plasmid pUC19Bgl, completely digested with Bglll/Hindlll. An aliquot of the ligation mixture is added to calcium- treated, transformation-competent E. coli HB101 cells, βampicillin resistant E. coli transformants from each of the two transformations are grown in the presence of 100 mg l ampicillin. Plasmid DNA is prepared and analyzed by digestion with Bglll/Hindlll, Bglll/BstEII and Hindlll/BstEII. The two correct clones with the expected fragments are named pUC19Bgl/Bglll-Hindlll/yCNA1 and pUC19Bgl/Bglll-Hindlll/yCNA2, respectively. The DNA inserts in the two plasmids are confirmed by sequencing (using the Applied Biosystems DNA sequencer 370A).
The vector pUC19Bgl, used for the above ligations, is a modified pUC19 (Boehringer Mannheim GmbH, Germany). pUC19 is digested with the restriction enzyme BamHI and the sticky ends are flushed with the large fragment of Klenow polymerase. The blunt ended DNA is ligated with Bglll linkers (double-stranded octamers, the sense strand being 'CAGATCTG'; Boehringer), digested with Bglll and religated. An aliquot of the ligation mixture is transformed in HB101 cells. Plasmid DNA is prepared from 6 HB101 transformants and are analyzed by digestion with Scal/Bglll and Scal/BamHI. One correct clone with the expected fragments is named pUC19Bgl. The BamHI and Bglll restriction sites are both present in the vector pUC19Bgl. The plasmid pUC18Bgl is prepared in an identical manner from pUC18.
Example 2: Construction of vCNAIΔ and vCNA2Δ, C-terminal truncated versions of the genes encoding the isozymes (i.e. vCNA1 and vCNA2) for the catalytic subunit of yeast calcineurin
In order to obtain the above genes, PCR is performed on the complete yeast CNA1 and CNA2 (pUC19Bgl/ Bglll-Hindlll/ yCNA1 and pUC19Bgl/Bglll-Hindlll/yCNA2, as templates; see Example 1 ), using two pairs of deoxyoligoribonucleotides as primers (see SEQ ID NOs 1 , 5 and 2, 6). The yeast cDNA is amplified as described in Example 1. Two 1670 bp and 1530 bp Bglll-Hindlll fragments, encoding yCNAI Δ and yCNA2Δ (i.e. yCNA1 and yCNA2 lacking their putative autoinhibitory domains), are isolated. After digestion with Bglll/Hindlll, the fragments are ligated to the plasmid pUC19Bgl (see Example 1). DNA obtained from transformants are analyzed as described in Example 1). The two correct clones with the expected fragments are named pUC19Bgl/Bglll-Hindlll/yCNA1Δ and pUC19Bgl/Bglll- Hindlll/yCNA2Δ, respectively. The truncated gene fragments are confirmed by sequencing, as in Example 1.
Example 3: Construction of vKAID) and v2(AID), the gene fragments encoding the autoinhibitory peptides of yeast calcineurin vCNA1 and vCNA2
The Bglll-Xbal autoinhibitory sequences, y1 (AID) and y2(AID) (Cyert et al., Proc. Natl. Acad. Sci. USA (1991), 88, 7376-7380), are obtained by PCR using pUC19Bgl/Bglll-Hindlll/yCNA1 and pUC19Bgl/Bglll-Hindlll/yCNA2, as templates (see Example 1). The primers employed are depicted in SEQ ID NOs 7, 8 and 9, 10. The Bglll-Xbal fragments are subcloned in pUC19Bgl. The two clones with correct inserts are named pUC19Bgl/Bglll-Xbal/y1 (AID) and pUC19Bgl/Bglll-Xbal/y2(AID), respectively.
Example 4: Isolation of the yeast SUC2 terminator fragments
The SUC2 gene (Taussig et al., Nucleic Acids Res. (1983), 11 , 1943-1954) terminator is isolated as four unique fragments (-300 bp) by PCR, using yeast genomic DNA as template: (i) an EcoRI-Sacl fragment with primers in SEQ ID NOs 11 and 12; (ii) an Xbal- Sacl fragment with primers in SEQ ID NOs 13 and 12; (iii) a Bglll-Sacl fragment with primers in SEQ ID NOs 14 and 12; (iv) an EcoRI-Kpnl fragment with primers in SEQ ID NOs 11 and 15. All the three fragments are subcloned in pUC19 or pUC19Bgl and the DNA inserts are confirmed by DNA sequencing (see Example 1). The resulting plasmids are:
(i) 19/EcoRI-Sacl/SUC2t
(ii) pUC19/Xbal-Sacl/SUC2t
(iii) pUC19/Bglll-Sacl/SUC2t
(iv) pUC19/EcoRI-Kpnl/SUC2t Example 5: Construction of pRHIOC, which encodes the GAPCL promoter fused to a nuclear localization signal of the SV40 large T antigen which, in turn, is linked to the transcription-activation domain of ACE1 (i.e. ACE1C)
A 393 bp truncated version of the constitutive glyceraldehyde dehydrogenase promoter (GAPCLp) is cloned as a -670 bp Sall-EcoRI fragment (Meyhack et al., in Hershberger, Queener, Hegeman (ed.), Genetics and molecular biology of industrial microorganisms, 1989, p. 311-321. American Society for Microbiology, Washington, DC) into pBluescriptllKS- vector (Stratagene), yielding the plasmid pRH2. The -670 bp Sall-EcoRI insert in pRH2 contains a 276 bp Sall-BamHI fragment from pBR322 upstream of the GAPCLp.
A 80 bp EcoRI-Spel double-stranded DNA linker (see SEQ ID NO 16), encoding the nuclear localization signal (NLS) from the simian virus 40 Tantigen (Kalderon et al., Cell (1984), 39, 499-509; and Nelson et al., Mol. Cell. Biol. (1989), 9, 384-389), is subcloned in pRH2 and the DNA insert is confirmed by sequencing (see Example 1 ). One correct clone is referred to as pRH3.
The -304 bp Xbal-Bglll ACE1C transcriptional activation domain from the yeast transcriptional activator ACE1 (Munder et al., Mol. Cell. Biol. (1992), 12, 2091-2099) is isolated as a PCR product using two primers (see SEQ ID NOs 17 and 18) with the plasmid pTM4 as template (Munder et al., Mol. Cell. Biol. (1992), 12, 2091-2099). The Xbal-Bglll fragment is subcloned in pUC19Bgl. The insert is confirmed by sequencing (see Example 1 ) and it contains two extra nucieotides after the last complete codon at the 3' end of the gene fragment (see SEQ ID NO 18). The plasmid with the correct insert is named pUC19Bgl/Xbal-Bglll/ACEc_3.
The -670 bp Sall-EcoRI fragment from pRH2 and the -304 bp Xbal-Bglll fragment from pUC19Bgl Xbal-Bglll/ACEc_3 are subcloned in pUC19Bgl completely digested with Sail and Bglll. Correct clones are confirmed by appropriate restriction enzyme digests. One such clone is referred to as pRHIOC. Example 6: Construction of yeast expression vectors for the expression of ACE1 C- vKAID) and ACE1C-v2(AID): y1 (AID) and y2(AID) encode the autoinhibitory peptides of the yeast calcineurin catalytic subunits yCNA1 and yCNA2.
The -1075 bp Sall-Bglll fragment from pRHIOC (see Example 5), the Bglll-Xbal fragment from either pUC19Bgl/Bglll-Xbal/y1(AID) or pUC19Bgl/Bglll-Xbal/y2(AID) (see Example 3) and the -300 bp Xbal-Sacl fragment from ρUC19/Xbal-Sacl/SUC2t (see Example 4) are ligated to the vector pDP34 which has been completely digested with Sail and Sad. The plasmid pDP34 is an E. coli-S. cerevisiae shuttle vector, which contains the complete S. cerevisiae 2-micron plasmid and encodes the S. cerevisiae URA3 and dLEU2 genes as yeast selection markers (Meyhack et al., in Hershberger-CL; Queener-SW; Hegeman-G (ed.), Genetics and molecular biology of industrial microorganisms, 1989, p. 311-321. American Society for Microbiology, Washington, DC). After transformation in E. coli HB101 , DNA is prepared from 12 transformants. Analyses with Sall/Sacl and BamHI-Sacl confirm the correct clones. Two such clones are referred to as pMH10 [encoding y1 (AID)] and pCS100 [encoding y2(AID)].
A control plasmid, which contains only NLS-ACE1C under the control of the GAPCLp, is prepared by ligating the -1075 bp Sall-Bglll fragment from pRHIOC (see Example 5) and the -300 bp Bglll-Sacl fragment from pUC19/Bglll-Sacl/SUC2t (see Example 4) to the vector pDP34 which has been completely digested with Sail and Sad. The plasmid is named pRH C (Fig. 1).
Example 7: Construction of a yeast expression vector for the expression of ACE1C-- vKAIDHGIv..rVl (AID) and ACE1C-v2.AIDHGIv),.-v2(AID), encoding a fusion between the transcription-activation domain ACE1 C and duplicate fragments of the autoinhibitory domains of yCNA1 and vCNA2
The -1075 bp Sall-Bglll fragment from pRHIOC (see Example 5) and the Bglll-Xbal fragments from either pUC19Bgl Bglll-Xbal/y1 (AID) or pUC19Bgl/Bglll-Xbal/y2(AID) (see Example 3) are ligated to pUC19 which has been completely digested with Sail and Xbal. The two correct clones are named pUC19/Sall-Xbal/GAPFLp-NLS-ACE1C-y1(AID) or pUC19/Sall-Xbal/G APFLp-NLS-ACEI C-y2(AID). Unphosphorylated linkers (encoding a stretch of four glycines) with SEQ ID NO 19 are ligated to Xbal digested pUC19/Sall-Xbal/GAPFLp-NLS-ACE1C-y1(AID) or pUC19/Sall- Xbal/GAPFLp-NLS-ACE1C-y2(AID). The ligated molecules are isolated on a 1% agarose/Tris-acetate gel. The fragments are isolated, purified by GeneClean (Bio 101 , CA, USA) and re-annealed by incubating at 95°C followed by slow cooling to room temperature. The DNA obtained from HB101 transformants are analyzed on a 2% agarose gel. The clones which show a distinct increase in the molecular size of the Bglll-Xbal fragments from the ones obtained from the starting plasmids (see above, this Example) are named pUC19/Sall-Xbal/GAPFLp-NLS-ACE1C-y1(AID)-(Gly)4 and pUC19/Sall-Xbal/ GAPFLp-NLS- ACE1C-y2(AID)-(Gly)4.
A second copy of y1(AID) is isolated as a Spel-Hindlll fragment by PCR, using the primers in SEQ ID NOs 20 and 21 and the plasmid pUC19/Sall-Xbal/ GAPFLp-NLS-ACE1C-y1(AID) as template. This is subcloned along with a Hindlll-Sacl yeast PH05 transcriptional terminator fragment in pBluescriptKS+. One correct clone is referred to as pBluescriptKS+/Spel-Sacl/y1(AID)-PH05t.
A second copy of y2(AID) is isolated as a Spel-Sacl fragment by PCR, using the primers in SEQ ID NOs 22 and 12 and the plasmid pCS100 (see Example 6) as template. This is subcloned in pBluescriptKS+. One correct clone is referred to as pBluescriptKS+/Spel- Sacl/y2(AID)-SUC2t.
The -1100 bp Sall-Xbal fragment from pUC19/Sall-Xbal/GAPFLp-NLS-ACE1C-y1(AID)~ (Gly)4 and the Spel-Sacl fragment from pBluescriptKS+/Spel-Sacl/y1(AID)-PH05t are ligated to the vector pDP34 which has been completely digested with Sail and Sad. After transformation in E. coli HB101 , DNA is prepared from 12 transformants. Analyses with Sall/SacI and BamHI-Sacl confirm the correct clones. One such clone is referred to as pMH11 (encoding two copies of y1 (AID) linked by a glycine linker).
The -1100 bp Sall-Xbal fragment from pUC19/Sall-Xbal/GAPFLp-NLS-ACE1C-y2(AID)- (Gly)4 and the Spel-Sacl fragment from pBluescriptKS+/Spel-Sacl/y2(AID)-SUC2t are ligated to the vector pDP34 which has been completely digested with Sail and Sacl. As above, analyses with Sall/SacI and BamHI-Sacl confirm the correct clones. One such clone is referred to as pCS101 (encoding two copies of y2(AID) linked by a glycine linker).
Example 8: Construction of hCNRA2 and hCNRA2Δ. the complete and truncated genes encoding the catalytic subunit of human calcineurin
The 3' end (~1280bp) of the human gene (Guerini et al., Proc. Natl. Acad. Sci. USA (1989) 86, 9183-9187) is isolated as two fragments (a -563 bp Ncol-Sacl fragment and a -713 bp Sacl-EcoRI fragment) from human fetal brain cDNA library (Stratagene) by PCR, using two pairs of primers with SEQ ID NOs 23, 24 and 25, 26. They are subcloned in the modified pUC19Bgl vector pUC19bg_nc, in which an Ncol site has been introduced (with Ncol linkers; Boehringer) at the Smal site of pUC19Bgl (see Example 1 ). Four individual clones with -1280 bp inserts are sequenced (using the Applied Biosystems DNA sequencer 370A). One correct clone is named pUC19bg_nc/Ncol-EcoRI/3'hCNRA2.
The -300 bp 5' end (a Bglll-Ncol fragment) of hCNRA2 is constructed with two overlapping deoxyoligoribonucleotides (which are chemically synthesized using yeast-biased codons; see SEQ ID NOs 27 and 28). First, primer extension is performed which is followed by a PCR with primers (see SEQ ID NOs 29 and 30; which code for the sense and the anti- sense strand of the 5' and 3' ends of the -300 bp fragment). The Bglll-Ncol fragment is subcloned in pUC19bg_nc (see above; this Example). Six individual clones with -300 bp inserts are sequenced (using the Applied Biosystems DNA sequencer 370A). One correct clone is named pUC19bg_nc/Bglll-Ncol/5'hCNRA2.
The complete hCNRA2 gene is assembled from the chemically synthesized -300 bp Bglll- Ncol fragment and the -1280 bp Ncol-EcoRI fragment by subcloning in pUC18Bgl (constructed in the way pUC19Bgl is made; Example 1). Six individual clones are analyzed by restriction enzyme digests. One correct cloned is named pK010.
The complete hCNRA2 gene (but lacking the DNA encoding the 2 amino acids at the N-terminus, Met1, Ala2) is isolated as a Bglll-EcoRI fragment by PCR, using primers with SEQ ID NOs 31 and 32 and pKO10 as template. The gene encoding the C-terminal truncated version of hCNRA2 (i.e. hCNRA2Δ), which lacks the autoinhibitory domain (and also the DNA encoding the N-terminal residues, Met1, Ala2), is isolated as a Bglll-EcoRI fragment by PCR, using primers with SEQ ID NOs 31 and 33 and pK010 as template.
Example 9: Construction of two yeast expression vectors for the expression of ACE1C- h(AID) and ACE1C-h(AIDHGIv)4-h(AIDV. h(AID) encodes the autoinhibitory peptide of the human brain calcineurin catalytic subunit hCNRA2
Using the plasmid pUC19Bgl/Bglll-EcoRI/hCNRA2 as a PCR template, one copy of the autoinhibitory domain (Hubbard et al., Biochemistry (1989), 28, 1868-1874 and Hashimoto et al., J. Biol. Chem. (1990), 165, 1924-1927) from hCNRA2 is isolated as a Bglll-Xbal fragment (the PCR primers are described in SEQ ID NOs 34 and 35). The ACEIC-h(AID) fusion and the expression plasmid (based on pDP34; see Example 6) is constructed, as described in Example 6. The plasmid is named pCS102.
The second copy of h(AID) is isolated as a Spel-Sacl fragment using the primers with SEQ ID NOs 36 and 12 and pCS102 as template (similar to Example 7). The expression plasmid for ACE1C-h(AID)-(Gly)4-h(AID) in pDP34 is constructed in an identical manner to that of pCS101 (see Example 7). The plasmid is named pCS103.
Example 10: Construction of pRH1, the vector for expression of fusion genes between the DNA-binding domain of ACE1 (i.e. ACE1 N) and a gene of interest
The plasmid pTM9 (Munder et al., Mol. Cell. Biol. (1992), 12, 2091-2099) is digested with EcoRI and Kpnl. The -4400 bp fragment is isolated on a 1% agarose gel and purified by GeneClean®. A -300 bp EcoRI-Kpnl fragment from pUC19/EcoRI-Kpnl/SUC2t (see Example 4) is ligated to the -4400 bp linearized fragment and transformed in E. coli. Analysis of transformants with EcoRI and Kpnl yielded a plasmid where the CYC1 terminator in pTM9 is replaced by the SUC2 terminator fragment. This plasmid is named pRH1 (Fig. 2) and is a vector which can be used for integration of any gene which is fused to ACE1 N (the DNA-binding domain of the yeast transcription factor ACE1) into the yeast chromosome. Example 11 : Construction of veast expression vectors for the expression of ACE1N- vCNA1-PHQ5t. ACE1 N-vCNA2-PHQ5t, ACE1 N-vCNA1Δ-PHQ5t. ACE1 N- yCNA2Δ-PHQ5t, ACE1 N-hCNRA2-SUC2t and ACE1 N-hCNRA2Δ-SUC2t in PRH1
The subcloning of ACE1N-yCNA1-PH05t, ACE1N-yCNA2-PH05t, ACE1N-yCNA1Δ-PH05t and ACE1 N-yCNA2Δ-PH05t in pRH1 is performed in an identical manner. A Bglll-Hindlll fragment containing the complete yCNA1 or yCNA2 genes (or their truncated versions; Examples 1 and 2) and the Hindlll-Kpnl fragment of the yeast PH05 transcription terminator are ligated to pRH1 (see Example 10) which is completely digested with Bglll and Kpnl. Restriction enzyme analysis of DNA, obtained from E. coli transformants, reveals the correct clones. The plasmids are named pMH6, pMH7 (encoding ACE1N-yCNA1 and ACE1N- yCNAIΔ, respectively) and pMH21, pMH22 (encoding ACE1N-yCNA2 and ACE1 N-yCNA2Δ, respectively)
The Bglll-EcoRI fragments containing the hCNRA2 and hCNRA2Δ genes (see Example 8; both lacking the DNA encoding the N-terminal residues, Met1, Ala2) are subcloned directly in Bglll-EcoRI digested pRH1. The plasmids are named pK011 , pK012 (encoding the ACE1 N-hCNRA2 and ACE1 N-hCNRA2Δ fusions, respectively).
Example 12: Construction of a veast vector for expression of vTPK1. the complete gene encoding the catalytic subunit of veast cAMP-dependent protein kinase
A -1200 bp Bglll-EcoRI fragment of the yTPK1 gene (the complete coding sequence; Toda et al., Cell (1987), 50, 277-287) is isolated from the yeast genome by PCR using the primers with SEQ ID NOs 37 and 38. For the expression of yTPK1 as a ACE1 N-yTPK1 fusion, the -1200 bp Bglll-EcoRI fragment of yTPK1 is subcloned in pRH1 (see Example 10). One clone, which contains the correct insert (confirmed by restriction enzyme analysis and DNA sequencing) is named pSK1 A. Example 13: Construction of a veast expression vector for expression of the regulatory subunit of yTPK1 , i.e. yBCYI : the complete gene which also encodes the inhibitory peptide of yTPK1
A -1260 bp BamHI-EcoRI fragment of the yeast BCY1 gene (the complete coding sequence, Toda et al., Mol. Cell. Biol. (1987), 7, 1371-1377) is isolated from the yeast genome by PCR, using the primers with SEQ ID NOs 39 and 40. For the expression of yBCYI as a ACE1C-yBCY1 fusion, the -1075 bp Sall-Bglll fragment from pRHIOC (see Example 5), the -1260 bp BamHI-EcoRI fragment of the yeast BCY1 gene and the -300 bp EcoRI-Sacl fragment from pUC19/EcoRI-Sacl/SUC2t (see Example 4) are ligated to the vector pDP34 which has been completely digested with Sail and Sad. One clone, which contains the correct insert (confirmed by restriction enzyme analysis and DNA sequencing) is named pSK5.
Example 14: Construction of veast expression vectors for the expression of ACE1C- BCYKwt ID) ACE1 C-BCY1 (Mut1 ID) and ACE1 C-BCY1 (Mut2 ID) which encode a single copy of the gene fragments encoding the inhibitory peptide (ID) of veast BCY1 (wild type, pseudosubstrate and a mutated pseudosubstrate)
The -1075 bp Sall-Bglll fragment from pRHIOC (see Example 5) and double-stranded linkers (Bglll-Xbal fragments) encoding BCYI(wt-ID) (SEQ ID NO 41), BCY1 (Mut1 -ID) (SEQ ID NO 42) and BCY1(Mut2-ID) (SEQ ID NO 43) are ligated to pUC19 completely digested with Sail and Xbal. The resulting correct clones are named pUC19/Sall-Xbal/GAPCLp- ACE1C-BCY1 (wt-ID), pUC19/Sall-Xbal/GAPCLp-ACE1C-BCY1 (Mut1 -ID) and pUC19/Sall- Xbal/GAPCLp-ACE1 C-BCY1 (Mut2-ID).
The individual Sall-Xbal fragments from the above plasmids and a Xbal-Sacl fragment from pUC19/Xbal-Sacl/SUC2t (Example 4) are subcloned in pDP34 (as described in Example 6). The expression plasmids are named pSK26, pSK21 and pSK22 [encoding ACE1C- BCYI(wt-ID)], pSK21 [encoding ACE1C-BCY1(Mut1-ID)] and pSK22 [encoding ACE1C- BCY1 (Mut2-ID)].
Example 15: Construction of veast expression vectors for the expression of ACE1 C- BCYKMut/l ID)-(Glv)4-BCY1 (Mut1 ID) and ACE1C-BCY1 (Mut2 ID)-(Glv)4- BCY1(Mut2 ID), the gene fragments encoding the inhibitory peptides of veast BCY1 (pseudosubstrate and a mutated pseudosubstrate): two copies linked by qlycine linkers
The second copies of BCYI(wt-ID), BCY1(Mut1-ID) and BCY1 (Mut2-ID) are isolated by PCR using the primers (SEQ ID NOs 44 and 45), the templates being pSK26, pSK21 and pSK22, respectively. Expression plasmids in pDP34 are made as described in Example 7.
Example 16: Isolation of the three fragments from human p70 s6 kinase (p70s6k). the complete gene, a C-terminal truncated version of p70s6k (p70s6kΔC) and an N-terminal truncated version of p70s6k (p70s6kΔN), for expression as fusion genes with ACE1 N
In order to obtain the genes encoding p70s6k, p70s6kΔC and p70s6kΔN, for corred in- frame fusion with the DNA-binding domain of the yeast transcription activator ACE1 , PCR is performed on the cDNA encoding the mitogen-activated S6 kinase (i.e. p70s6k) obtained from the rat liver (Kozma et al., Proc. Natl. Acad. Sci. USA (1990), 87, 7365-7369). The rat gene encodes a polypeptide identical to the human protein. Three pairs of deoxyoligoribo¬ nucleotides are used as primers (see SEQ ID NOs 45 and 46; 45 and 47 and 48 and 46).
The genes, obtained as BamHI-Xbal/ BamHI-EcoRI fragments, are subcloned in pRH1 (see Example 10). The resulting plasmids are named pSK18 (encoding wild type (wt) p70s6k), pSK6 (encoding p70s6kΔC) and pSK27 (encoding p70s6kΔN), respectively.
Example 17: Construction of veast expression vedors for the expression of ACE1C-s6k(wt AID), ACE1C-s6k(Mut1-AID) and ACE1C-s6k(Mut2-AID): single copies of the gene fragments encoding the autoinhibitory peptides of human p70 s6 kinase (wild type, pseudosubstrate and a mutated pseudosubstrate)
The Bglll-EcoRI -312 bp fragments, containing the wild type or mutated autoinhibitory peptide sequences (Banerjee, et al., Proc. Natl. Acad. Sci. USA (1990), 87, 8550-8554) are subcloned in the context of the activation domain of the yeast transcriptional activator ACE1 in the expression vector pDP34 (as in Example 6). The pair of deoxyoligoribonucleotides with SEQ ID NOs 49 and 46 are used to isolate the wild type (wt) and the two mutated sequences as Bglll-EcoRI fragments. The resulting plasmids are named pSK11 (wt), pSK13 (Mut1 ) and pSK12 (Mut2).
The four Ser/Thr residues comprising the autophosphorylation sites in the autoinhibitory peptide of p70s6k (Ferrari et al., Proc. Natl. Acad. Sci. USA (1992), 89, 7282-7286) are mutated to Ala in the Mut1-AID sequence (Ferrari et al., J. Biol. Chem. (1993), 268, 16091- 16094), whereas in Mut2-AID the Ser/Thr residues are replaced by the acidic amino acids Glu/ Asp (Flotow et al., J. Biol. Chem. (1992), 267, 3074-3078).
A Bglll-EcoRI -513 bp fragment (comprising the above -312 bp fragment and a 5' extension of -200 bp) is subcloned by PCR from the wt gene and the mutated sequences, which encode the Mut1-AID and Mut2-AID mutations. The pair of deoxyoligoribonucleotides with SEQ ID NOs 50 and 46 are used to isolate the wt and the two mutated sequences as Bglll- EcoRI fragments. They are cloned as ACE1C fusions in pDP34, as detailed in Example 6. They are referred to as pSK8 (wt), pSK10 (Mut1) and pSK9 (Mut2).
Example 18: Construction of plasmids for the expression of p70s6k. p70s6kΔC and p70s6kΔN from veast multi-copy vectors
A -670 bp Sall-Bglll fragment (containing the GAPCL promoter) is isolated from pRH2 (see Example 5) by PCR using the primers with the SEQ ID NOs 51 and 52.
The above Sall-Bglll fragment, the BamHI-Xbal/ BamHI-EcoRI fragments (encoding the sequences of p70s6k, p70s6kΔC and p70s6kΔN; see Example 16) and a Xbal-Sacl/ EcoRI- Sacl fragment of the SUC2 terminator (see Example 4) are subcloned in pDP34 digested completely with Sail and Sad. The correct clones are named pSK16 (encoding p70s6k), pSK18 (encoding p70s6kΔC) and pSK28 (encoding p70s6kΔN).
It is observed that yeast transformants of pSK16 yield an active protein. No protein is seen in cells harboring pSK18 and pSK28. However, the amount of mRNA obtained from the latter is the same as in cells expressing full length p70S6k. Example 19: Chromosomal integration of ACE1 N fusion genes in the veast strain TFY2
The Bio-Rad gene pulser is employed for transformation of yeast cells (see Table 1) by electroporation (Methods. Enzymol. (1991), 194, 182-187). The strain TFY2 (Matα his ura3- 52 tro1-285 acel LEU2::YipCL CUP1) (Munder et al., Mol. Cell. Biol. (1992), 12, 2091-2099) is used for all integrations of ACE1N-gene fusions into the yeast chromosome. Correct gene integration and gene replacement events are verified by PCR with primers flanking the insertion sites. Subsequently, the amplified fragments are analyzed by agarose gel electrophoresis.
TABLE 1 : (Yeast strains used)
Fusion Strain Genotype
- TFY2 Matα his ura3-52 trp1-285 acel LEU2::YipCL CUP1r
ACE1 N-yCNA1 CNY1 Matα his ura3-52 acel LEU2::YipCL CUP1rTRP1 ::pMH6
ACE1 N-yCNAlΔ CNY2 Matα his ura3-52 acel LEU2::YipCL CUP1rTRP1 ::PMH7
ACE1 N-yCNA2 CNY3 Matα his ura3-52 acel LEU2::YipCL CUP1rTRP1 ::PMH21
ACE1 N-yCNA2Δ CNY4 Matα his ura3-52 acel LEU2::YioCL CUP1rTRP1 ::oMH22
ACE1 N-hCNRA2 CNY5 Matα his ura3-52 acel LEU2::YipCL CUP1fTRP1 ::pK011
ACE1 N-hCNRA2Δ CNY6 Matα his ura3-52 acel LEU2::YipCL CUP1rTRP1 ::pK012
ACE1 N-yTPK1 CNY7 Matα his ura3-52 acel LEU2::YipCL CUP1rTRP1 ::pSK1 A
ACE1 N-yp70s6k CNY8 Matα his ura3-52 acel LEU2::YipCL CUP1rTRP1 ::pSK18
ACE1 N-yp70s6kΔC CNY9 Matα his ura3-52 acel LEU2::YipCL CUP1rTRP1 ::pSK6
AC0E1 N-yp70s6kΔN CNY10 Matα his ura3-52 acel LEU2::YipCL CUP1rTRP1 ::pSK27
Example 20: Yeast transformations with plasmids. in strains harboring gene fusions with ACE1N
Yeast strains harboring ACE1N gene fusions are transformed with plasmids bearing the different ACE1C fusions as described in Example 19. The transformants are depicted in Table 2.
TABLE 2: plasmids and the corresponding strains used for creating protein-interactions
Figure imgf000029_0001
pSK13 312bp Mut1 (AID) CNY8 CNY36 ++ ++ pSK12 312bp Mut2(AID) CNY8 CNY37 - - pSK8 513bp wt(AID) CNY8 CNY38 + + pSK10 513bp Mut1 (AID) CNY8 CNY39 ++ ++ pSK9 513bp Mut2(AID) CNY8 CNY40 - - pSK11 312bp wt(AID) CNY9 CNY41 - - pSK13 312bp Mut1 (AID) CNY9 CNY42 - - pSK12 312bp Mut2(AID) CNY9 CNY43 - - pSK8 513bp wt(AID) CNY9 CNY44 - - pSK10 513bp Mut1(AID) CNY9 CNY45 - - pSK9 513bp Mut2(AID) CNY9 CNY46 - - pSK11 312bp t(AID) CNY10 CNY47 - - pSK13 312bp Mut1(AID) CNY10 CNY48 - - pSK12 312bp Mut2(AID) CNY10 CNY49 - - pSK8 513bp wt(AID) CNY10 CNY50 - - pSK10 513bp Mut1 (AID) CNY10 CNY51 - - pSK9 513bp Mut2(AID) CNY10 CNY52 - - nd = not de ermined
Example 21 : Assay for copper resistance: induction of metallothionein expression
Equal numbers of cells are spotted onto SD-agar plates (2 % glucose, 0.67 % yeast nitrogen base without amino acids, 2 % agar) containing (a) no CuS04) (b) 100 μM CuS04 and (c) 200 μM CuS04 (Munder et al., Mol. Cell. Biol. (1992), 12, 2091-2099). The results are portrayed in Table 2.
Example 22: β-qalactosidase assay
Yeast cells (Example 19) are grown in YPD medium (1 % bacto-yeast extract, 2 % bacto- peptone, 2 % glucose) for 17 h at 30°C. Cells are first washed in SD medium (0.67 % yeast nitrogen base without amino acids, 2 % glucose) and then the transcription of the reporter gene is induced. Induction and permeabilization of cells are performed as described previously (Fϋrst et al., Cell (1988), 55, 705-717). β-galactosidase activity, measured as o-nitrophenyl-β-D-galacto-pyranoside hydrolysis at 420 nm, is normalized to cell culture density and expressed as arbitrary units. The activity in the control strains, harboring the plasmid pRH14C, is set to the value 1. The results are portrayed in Table 2.
Example 23: Disruption of protein-peptide interactions with small organic compounds
Cells are initially grown in YPD, as in Example 22. After washing in SD, cells are preincubated with small organic compounds (dissolved in dimethyl sulphoxide and 10-20 μmolar in final concentration) for 90 min at 30°C. Later, β-galactosidase activity is measured, exactly as in Example 22.
Example 24: Disruption of protein-peptide interaction in CNY15 with the immunosuppressants cyclosporin A and FK506
Three individual transformants from CNY15 (see Table 2) are grown in YPD, as in Example 22. In the strains, interaction between y1CNA1 D (yeast calcineurin isozyme 1 from which the C-terminal autoinhibitory domain is deleted) and y1(AID)-Gly -y1 (AID) [the autoinhibitory domain of the same enzyme; two copies linked by 4 glycines] are established. After washing in SD, cells are preincubated with cyclosporin A (CsA; final concentrations: 0, 5 and 10 μg/ ml) and FK506 (final concentrations: 0, 0.5 and 1 μg/ ml) for 15 h at 30°C. Later, β-galactosidase activity is measured, as in Example 22. As control, three individual transformants from CNY16 (see Table 2) are used. The results, an average of three transformants (in duplicate), are depicted in Table 3. The units shown are arbitrary (see Example 22).
TABLE 3. Disruption of the protein-peptide interaction in CNY15 Strain Compound Final concentration Relative β-Galactosidase in μg/ ml units
CNY15 CsA 0 3
CNY15 CsA 5 1.8
CNY15 CsA 10 1
CNY15 FK506 0 3
CNY15 FK506 0.5 1.6
CNY15 FK506 1 1
CNY16 CsA/ FK506 0 1
CNY16 CsA/ FK506 5/0.5 0.95
CNY16 CsA/ FK506 10/1 0.92
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT:
(A) NAME: CIBA-GEIGY AG
(B) STREET: Klybeckstr. 141
(C) CITY: Basel
(E) COUNTRY: Switzerland
(F) POSTAL CODE (ZIP) : 4002
(G) TELEPHONE: +41 61 69 11 11 (H) TELEFAX: + 41 61 696 79 76 (I) TELEX: 962 991
(ii) TITLE OF INVENTION: Dual hybrid system
(iii) NUMBER OF SEQUENCES: 52
(iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
(2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Bglll site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 10..28
(D) OTHER INFORMATION: /function= "PCR fragment" /note= "fragment of yest CNAl gene"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
ATAGATCTAA TGTCGAAAGA CTTGAATT 28
(2) INFORMATION FOR SEQ ID NO: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Hindu site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: complement (9..30)
(D) OTHER INFORMATION: /function= "PCR fragment"
/note= "5' end anti-sense strand of conding sequence of yeast CNAl"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: ATAAGCTTTC ACAGTTGTGG CTTTTTCTCC 30
(2) INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function--- "Bglll site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 10..29
(D) OTHER INFORMATION: /function= "PCR primer" /note= "fragment of yeast CNA2 gene"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
ATAGATCTAA TGTCTTCAGA CGCTATAAG 29
(2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Hindlll site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: complement (9..30)
(D) OTHER INFORMATION: /function= "PCR fragment" /note= "5' end anti-sense strand of coding sequence of CNA2"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
ATAAGCTTCT ATTTGCTATC ATTCTTTGCA 30
(2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Hindlll site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: complement (9..30) (D) OTHER INFORMATION: /function= "PCR primer"
/note= "5' anti-sense strand of coding sequence of CNAl delta"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
ATAAGCTTCT ACAAACCTTC AGTCCCACGA 30
(2) INFORMATION FOR SEQ ID NO: 6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /functions "Hindlll site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: complement (9..31)
(D) OTHER INFORMATION: /function= "PCR primer"
/note= "51 end anti-sense strand of coding sequence of CNA2 delta"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
ATAAGCTTCT ATAAACCCTT TACACCATTA G 31
(2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Bglll site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 10..28
(D) OTHER INFORMATION: /function= "PCR primer" /note= "fragment of yl(AID) from CNAl"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
ATAGATCTGG GTTTGAATGA AACGCTAA 28
(2) INFORMATION FOR SEQ ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8 (D) OTHER INFORMATION: /function--- "Xbal site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: complement (9..26)
(D) OTHER INFORMATION: /function= "PCR primer"
/note= "5" end anti-sense strand of coding sequence of yl(AID) from CNAl"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:
TATCTAGACT TTAATATTTT TTCGTA 26
(2) INFORMATION FOR SEQ ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Bglll site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 10..29
(D) OTHER INFORMATION: /function= "PCR primer" /note= "fragment of y2 (AID) from CNA2"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: ATAGATCTGG GTTTAGATGA AGCCCTGTC 29
(2) INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Xbal site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: complement (9..28)
(D) OTHER INFORMATION: /function= "PCR fragment" /note= "5' end anti-sense strand of coding sequence of y2 (AID) "
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
ATTCTAGATT TCTGCCAAAC TTTTTCGT 28
(2) INFORMATION FOR SEQ ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "EcoRI site"
(ix) FEATURE:
(A) NAME/KEY: terminator
(B) LOCATION: 9..28
(D) OTHER INFORMATION: /standard_name= "SUC2 terminator" /note= "fragment for PCR"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:
ATGAATTCAG GTTATAAAAC TTATTGTC 28
(2) INFORMATION FOR SEQ ID NO: 12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Sad site"
(ix) FEATURE:
(A) NAME/KEY: terminator
(B) LOCATION: complement (9..26)
(D) OTHER INFORMATION: /standard_name= "SUC2 terminator" /note= "Anti-sense strand fragment for PCR"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
TAGAGCTCGG TCCATCCTAG TAGTGT 26
(2) INFORMATION FOR SEQ ID NO: 13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Xbal site"
(ix) FEATURE:
(A) NAME/KEY: terminator
(B) LOCATION: 9..28
(D) OTHER INFORMATION: /standard_name= "SUC2 terminator" /note= "fragment for PCR"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:
ATTCTAGAAG GTTATAAAAC TTATTGTC 28
(2) INFORMATION FOR SEQ ID NO: 14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid (C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Bglll"
(ix) FEATURE:
(A) NAME/KEY: terminator
(B) LOCATION: 9..28
(D) OTHER INFORMATION: /standard_name= "SUC2 terminator" /note= "fragment for PCR"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:
ATAGATCTAG GTTATAAAAC TTATTGTC 28
(2) INFORMATION FOR SEQ ID NO: 15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Kpnl site"
(ix) FEATURE: (A) NAME/KEY: terminator
(B) LOCATION: complement (9..26)
(D) OTHER INFORMATION: /standard_name= "SUC2 terminator" /note= "anti-sense fragment for PCR"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:
TAGGTACCGG TCCATCCTAG TAGTGT 26
(2) INFORMATION FOR SEQ ID NO: 16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 78 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1..4
(D) OTHER INFORMATION: /function= "EcoRI site"
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: complement (75..78)
(D) OTHER INFORMATION: /function= "Spel site"
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 5..74
(D) OTHER INFORMATION: /note= "Sense and anit-sense strand of nuclear localization signal of SV40 T antigene using yeast codons" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:
AATTCATGGA CAAGGTCTTC AGAAACTCTT CCAGAACTCC ACCAAAGAAG AAGAGAAAGG 60
TTGAAGACCC AGCACTAG 78
(2) INFORMATION FOR SEQ ID NO: 17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Xbal site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 10..26
(D) OTHER INFORMATION: /function= "PCR fragment"
/note= "yeast ACEl transcription activation domain fragment"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:
TATCTAGAGG ACGTTCTTTT GGGCCT 26
(2) INFORMATION FOR SEQ ID NO: 18:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Xbal site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: complement (11..29)
(D) OTHER INFORMATION: /function= "PCR fragment"
/note= "5' anti-sense strand of ACEl transcription activation domain"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:
TAAGATCTGC TTGTGAATGT GAGTTATGC 29
(2) INFORMATION FOR SEQ ID NO: 19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: complement (1..4)
(D) OTHER INFORMATION: /function= "Xbal site" ( ix ) FEATURE :
(A) NAME/KEY: misc_feature
(B) LOCATION: 19..22
(D) OTHER INFORMATION: /function= "Xbal site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 6..17
(D) OTHER INFORMATION: /function= "Glycine linker"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:
CTAGTGGTGG CGGTGGCTGA TC 22
(2) INFORMATION FOR SEQ ID NO: 20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Spel site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 9..27
(D) OTHER INFORMATION: /function= "PCR fragment"
/note= "sense strand of yl(AID) (second copy) from yeast CNAl" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:
ATACTAGTGG TTTGAATGAA ACGCTAA 27
(2) INFORMATION FOR SEQ ID NO: 21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
( D) OTHER INFORMATION : /function= "Hindlll "
( ix ) FEATURE :
(A) NAME/KEY: mat_peptide
(B) LOCATION: complement (9..30)
(D) OTHER INFORMATION: /function= "PCR fragment"
/note= "5" anti-sense strand of coding sequence of yl(AID) (for second copy) from yeast CNAl"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:
ATAAGCTTTC ACTTTAATAT TTTTTCGTAG 30
(2) INFORMATION FOR SEQ ID NO: 22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid (C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Spel site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 9..29
(D) OTHER INFORMATION: /function= "PCR fragment"
/note= "fragment of y2 (AID) (second copy) from CNA2"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:
ATACTAGTGG ATTCTCTCCA CCACATAGA 29
(2) INFORMATION FOR SEQ ID NO: 23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 3..24
(D) OTHER INFORMATION: /function= "PCR fragment" /note= "fragment of human CNRA2 gene" ( ix ) FEATURE :
(A) NAME/KEY: misc_feature
(B) LOCATION: 11..16
(D) OTHER INFORMATION: /function--- "Ncol site"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:
GTGGTGACAT CCATGGCCAA TTTT 24
(2) INFORMATION FOR SEQ ID NO: 24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: complement (1..25)
(D) OTHER INFORMATION: /function= "PCR primer"
/note= "anti-sense fragment of coding sequence of human CNRA2 gene"
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Sad site"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:
ATGAGCTCTA ATAATCGATA ACAAA 25 (2) INFORMATION FOR SEQ ID NO: 25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 1..25
(D) OTHER INFORMATION: /function= "PCR fragment" /note= "fragment of human CNRA2 gene"
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 5..10
(D) OTHER INFORMATION: /function-- "Ncol site"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:
ATTAGAGCTC ATGAAGCTCA AGATG 25
(2) INFORMATION FOR SEQ ID NO: 26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 47 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE: (A) NAME/KEY: mat_peptide
(B) LOCATION: complement (9..47)
(D) OTHER INFORMATION: /function= "PCR fragment"
/note= "anti-sense strand of sequence coding for human CNRA2 gene"
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "EcoRI site"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:
ATGAATTCTCA CTGGGCACTA TGGTTGCCAG TCCCGTGGTT CTCAGT 47
(2) INFORMATION FOR SEQ ID NO: 27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 165 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 1..165
(D) OTHER INFORMATION: /function= "PCR fragment"
/note= "coding for first 55 amino acids of hCNRA2"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:
ATGGCTGCTC CAGAACCAGC TAGAGCTGCA CCACCACCAC CTCCACCACC TCCACCACCT 60
CCAGGTGCTG ACAGAGTCGT CAAAGCTGTC CCTTTCCCAC CAACACATCG CTTGACATCT 120 GAAGAAGTAT TTGATTTGGA TGGGATACCC AGGGTTGATG TTCTG 165
(2) INFORMATION FOR SEQ ID NO: 28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 165 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 9..161
(D) OTHER INFORMATION: /function= "PCR fragment"
/note= "anti-sense strand of of coding sequence of human CNR2 gene (yeast-biased codons)"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:
CCATGGATGT CACCACACAC TGTGATTGGA GCTTCTACTT CTATCATGGT TTTCTCTCTC 60
CGAAGGATGG CAGCACCCTC ATTGATAATT CTAAGCGCAA TTTCTTCATC TACTCGACCT 120
TCTTTCACCA AGTGGTTCTT CAGAACATCA ACCCTGGGTA TCCCA 165
(2) INFORMATION FOR SEQ ID NO: 29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Bglll site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 10..29
(D) OTHER INFORMATION: /function.- "PCR fragment" /note= "fragment of human hCNRA2"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:
ATAGATCTCA TGGCTGCTCC AGAACCAGC 29
(2) INFORMATION FOR SEQ ID NO: 30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: complement (2..24)
(D) OTHER INFORMATION: /function= "PCR fragment" /note= "anti-sense strand of human CNRA2"
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 6..11 (D) OTHER INFORMATION: /function--- "Ncol site"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:
ATTGGCCATG GATGTCACCA CACA 24
(2) INFORMATION FOR SEQ ID NO: 31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Bglll site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 10..29
(D) OTHER INFORMATION: /function= "PCR primer" /note= "fragment of human CNRA2 gene"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:
ATAGATCTTG CTCCAGAACC AGCTAGAGC 29
(2) INFORMATION FOR SEQ ID NO: 32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid (C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_ eature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /functiθn= "EcoRI site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: complement (9..28)
(D) OTHER INFORMATION: /function= "PCR fragment"
/note= "5' end of anti-sense strand of human CNRA2 gene"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:
ATGAATTCTC ACTGGGCAGT ATGGTTGC 28
(2) INFORMATION FOR SEQ ID NO: 33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "EcoRI site" ( ix ) FEATURE :
(A) NAME/KEY: mat_peptide
(B) LOCATION: complement (9..29)
(D) OTHER INFORMATION: /function= "PCR fragment"
/note= "5" end of anti-sense strand of human CNRA2 delta"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:
ATGAATTCTC ATATTGCTTT TTCAGCCTC 29
(2) INFORMATION FOR SEQ ID NO: 34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D ) OTHER INFORMATION : /function= " Bglll site"
( ix ) FEATURE :
(A) NAME/KEY: mat_peptide
(B) LOCATION: 10..29
(D) OTHER INFORMATION: /function= "PCR fragment"
/note= "fragment of h(AID) from human CNRA2 gene"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:
ATAGATCTAG GATTCTCTCC ACCACATAG 29 (2) INFORMATION FOR SEQ ID NO: 35:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Xbal site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: complement (9..29)
(D) OTHER INFORMATION: /function= "PCR fragment"
/note= "5' end of anti-sense strand of coding sequence of y2 (AID) from human CNA2 gene"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:
ATTCTAGAAT CTTGCTGTAC AGCATCTTT 29
(2) INFORMATION FOR SEQ ID NO: 36:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic) ( ix ) FEATURE :
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Spel site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 9..29
(D) OTHER INFORMATION: /function= "PCR fragment"
/note= "fragment of h(AID), (second copy) from human CNRA2 gene"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:
ATACTAGTGG ATTCTCTCCA CCACATAGA 29
(2) INFORMATION FOR SEQ ID NO: 37:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Bglll site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 10..30
(D) OTHER INFORMATION: /function-** "PCR fragment" /note= "fragment of yeast TPK1 gene" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:
ATAGATCTTA TGTCGACTGA AGAACAAAAT 30
(2) INFORMATION FOR SEQ ID NO: 38:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Hindlll site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: complement (9..28)
(D) OTHER INFORMATION: /function= "PCR fragment"
/note= "5' end of antisens strand of coding sequence of yeast TPK1 gene"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:
ATGAATTCTT AGAAGTCCCG GAAAAGAT 28
(2) INFORMATION FOR SEQ ID NO: 39:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid (C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3.-8
(D) OTHER INFORMATION: /function= "BamHI site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 10..29
(D) OTHER INFORMATION: /function= "PCR fragment" /note= "fragment of yeast BCY1 gene"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:
ATGGATCCGA TGGTATCTTC TTTGCCCAA 29
(2) INFORMATION FOR SEQ ID NO: 40:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "EcoRI site"
(ix) FEATURE: (A) NAME/KEY: mat_peptide
(B) LOCATION: complement (9..28)
(D) OTHER INFORMATION: /function= "PCR fragment"
/note= "5' end of anti-sense strand of coding sequence of yeast BCY1 gene"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:
ATGAATTCTT AATGTCTTGT AGGATCAT 28
(2) INFORMATION FOR SEQ ID NO: 41:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 71 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1..5
(D) OTHER INFORMATION: /function= "Bglll site"
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: complement (67..71)
(D) OTHER INFORMATION: /function= "Xbal site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 6..66
(D) OTHER INFORMATION: /function= "PCR fragment" /note= "BCYKwt-ID) from yeast BCY1 gene" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:
GATCTGACAT CAACTCCTCC ACTCCCAATG CACTTCAACG CCCAAAGGCG TAATGCTGTT 60
AGTGGTTCTA G 71
(2) INFORMATION FOR SEQ ID NO: 42:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 71 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1..5
(D) OTHER INFORMATION: /function^ "Bglll site"
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: complement (68..71)
(D) OTHER INFORMATION: /function--- "Xbal site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 6..67
(D) OTHER INFORMATION: /function= "PCR fragment"
/note= "BCYKMutl-ID) from yeast BCYl gene. Nucieotides 53 and 55 are changed to replace ThrSer by AsnAla. "
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42: GATCTGACAT CAACTCCTCC ACTCCCAATG CACTTCAACG CCCAAAGGCG TAATGCTGTT 60
AGTGGTTCTA G 71
(2) INFORMATION FOR SEQ ID NO: 43:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 71 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 1..5
(D) OTHER INFORMATION: /function= "Bglll site"
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: complement (68..71)
(D) OTHER INFORMATION: /function= "Xbal site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 6..67
(D) OTHER INFORMATION: /function= "PCR fragment"
/note= "BCYl(Mut2-ID) from yeast BCY1 gene. Nucieotides 46, 47, 49, 51, 53 and 55 are changed to replace ArgArgThrSer by AlaAlaAsnAla"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:
GATCTGACAT CAACTCCTCC ACTCCCAATG CACTTCAACG CCCAAGCGGG CAATGCTGTT 60 AGTGGTTCTA G 71
(2) INFORMATION FOR SEQ ID NO: 44:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Spel site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 9..29
(D) OTHER INFORMATION: /function-- "PCR fragment"
/note= "BCYKwt-ID or Mutl-ID or Mut2-ID) (second copy) from yeast BCY1 gene"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:
ATACTAGTAC ATCAACTCCT CCACTCCCA 29
(2) INFORMATION FOR SEQ ID NO: 45:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "BamHI site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 10..29
(D) OTHER INFORMATION: /function= "PCR fragment" /note= "rat p70S6 kinase gene fragment"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:
ATGGATCCGA TGGCAGGAGT GTTTGACAT 29
(2) INFORMATION FOR SEQ ID NO: 46:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Xbal site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: complement (9..28)
(D) OTHER INFORMATION: /function= "PCR fragment" /note= "5'end anti-sense strand of coding sequence of rat p70S6 kinase gene"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:
ATTCTAGAGA AATCCCCAGG AGAGAATT 28
(2) INFORMATION FOR SEQ ID NO: 47:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "EcoRI site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: complement (9..28)
(D) OTHER INFORMATION: /function.- "PCR fragment"
/note= "5'end anti-sense strand of coding sequence of truncated p70S6k delta C gene"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:
ATGAATTCTC ATAGATTCAT ACGCAGGT 28
(2) INFORMATION FOR SEQ ID NO: 48:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "BamHI site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 10..30
(D) OTHER INFORMATION: /function= "PCR fragment" /note= "truncated p70S6k delta N gene"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:
ATGGATCCAG AATGTTTTGA GCTACTTCGG 30
(2) INFORMATION FOR SEQ ID NO: 49:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Bglll site" ( ix ) FEATURE :
(A) NAME/KEY: mat_peptide
(B) LOCATION: 10..32
(D) OTHER INFORMATION: /function= "PCR fragment"
/note= "sense strand of the -312 bp autoinhibitory sequence from p70S6K gene"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:
ATAGATCTGA AAGAAAAGTT TTCTTTTGAA CC 32
(2) INFORMATION FOR SEQ ID NO: 50:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function-- "Bglll site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 10..29
(D) OTHER INFORMATION: /function= "PCR fragment"
/note= "sense strand of -513 bp autoinhibitory sequence from p70S6k gene"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50: ATAGATCTTA ACTGGGAAGA GCTTTTGGC 29
(2) INFORMATION FOR SEQ ID NO: 51:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Sail site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 10..28
(D) OTHER INFORMATION: /function= "PCR fragment"
/note= "sense strand of -650 bp pBR322 (-275 bp) and the GAPCL (-396 bp) promoter fragment"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:
ATGTCGACGC TCTCCCTTAT GCGACTCC 28
(2) INFORMATION FOR SEQ ID NO: 52:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION: 3..8
(D) OTHER INFORMATION: /function= "Bglll site"
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: complement (9..28)
(D) OTHER INFORMATION: /function-- "PCR fragment"
/note= "5' anti-sense strand of the GAPCL (-396 bp) promoter fragment"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:
ATAGATCTTT TGTTTATGTG TGTTTATT 28

Claims

Claims
1. A transcription system for measuring the interaction between a phosphatase or kinase, or a mutein or fragment thereof that binds an autoinhibitory domain; with said autoinhibitory domain, comprising a) the DNA binding domain of a transcription factor and the transcription activation domain of a transcription factor that are separated, wherein one of the two transcription factor domains is linked to a polypeptide comprising a phosphatase or kinase or a fragment thereof that binds an autoinhibitory domain; and the other of the two transcription factor domains is linked to a polypeptide comprising an autoinhibitory domain that is capable of binding to the polypeptide linked to the first transcription factor domain, and b) a DNA that is transcribed when the DNA binding domain of said transcription factor and the transcription activation domain of said transcription fador are connected via the polypeptides linked thereto.
2. A transcription system according to claim 1 , wherein genuine phosphatase or kinase comprises an autoinhibitory domain.
3. A transcription system according to claim 1 , wherein the autoinhibitory domain and the fragment that binds an autoinhibitory domain originate from the same enzyme komplex.
4. A transcription system according to claim 1 , wherein the autoinhibitory domain and the fragment that binds an autoinhibitory domain originate from the same enzyme.
5. A transcription system according to claim 1 , wherein said phosphatase or kinase or the mutein or fragment of said phosphatase or kinase has a free AID binding domain.
6. A phosphatase or kinase according to claim 1 , selected from the group consisting of calcineurin, calcineurin that does not comprise the C-terminal 40 to 60 amino acids, PKA and p70S6 kinase.
7. An autoinhibitory domain according to claim 1, wherein the region that binds to the phosphatase or kinase according to claiml is present in 1 to 5 copies.
8. An autoinhibitory domain according to claim 7, wherein said region is present in 2 to 4 copies.
9. An autoinhibitory domain according to claim 7, wherein these binding regions are the same or different.
10. An autoinhibitory domain according to claim 7, wherein the binding regions are connected directly or via spacer groups.
11.An autoinhibitory domain according to claim 1 , selected from the group consisting the autoinhibitory domain of calcineurin, the regulatory subunit of PKA, and the autoinhibitory domain of p70S6; and fragments thereof that are still capable of binding to the phosphatase or kinase.
12. An autoinhibitory domain according to claim 1 , comprising a fragment of calcineurin comprising amino acid 508 to 533 and/or a fragment of p70S6 comprising amino acid 400 to 432.
13. A transcription system according to claim 1 , wherein the DNA binding domain of a transcription factor and the transcription activation domain of a transcription fador originate from the same transcription factor.
14. A transcription system according to claim 1 , wherein the transcription factor is selected from the group consisting of Acel , Gal4, VP16, p53 and lexA.
15. A transcription system according to claim 1 , wherein the transcription factor is Acel
16. A DNA binding domain according to claim 1 , comprising the N-terminal 122 amino acids of Acel .
17. A transcription activation domain according to claim 1 , comprising the C-terminal 100 amino acid of Acel .
18. An expression cassette for the expression of a fusion protein comprising the DNA binding domain or the transcription activation domain of a transcription factor according to claim 1 and a polypeptide comprising a phosphatase or kinase or a fragment thereof that binds an autoinhibitory domain according to claim 1 ; or a polypeptide comprising said autoinhibitory domain or an active fragment thereof, according to claim 1.
19. An expression cassette comprising a promoter that is operably linked to a DNA that is transcribed when the DNA binding domain of a transcription factor and the transcription activation domain of a transcription fador are joined via the polypeptides linked thereto according to claim 1; and to a sequence containing a transcription termination signal; with the proviso that said expression cassette is not already part of the natural genome of the host.
20. An expression cassette according to daim 19, wherein the promoter is selected from the group consisting of the CUP1 promoter, the Gall and the Gal10 promoter.
21.An expression cassette according to claim 19, wherein the promoter is the CUP1 promoter.
22. An expression cassette according to claim 19, wherein the DNA coding for a polypeptide encodes a polypeptide whose amount can be determined easily.
23.An expression cassette according to claim 19, wherein the DNA coding for a polypeptide encodes metallothionein, β-galactosidase or luciferase.
24. An expression cassette according to claim 19, wherein the DNA coding for a polypeptide encodes metallothionein or β-galactosidase.
25. A hybrid vector comprising an expression cassette according to claim 18 or 19.
26.A microbiological host comprising a transcription system according to claiml .
27.A microbiological host according to claim 26, selected from the group consisting of yeasts and bacteria.
28.A microbiological host according to claim 26, characterized in that it is a yeast cell.
29.A microbiological host according to claim 26, characterized in that it is Saccharomyces cerevisiae.
30. Method for the identification of a calcineurin agonist and antagonist comprising a) treating a microbiological host according to claim 26 with a test compound, and b) determining the amount of transcription activation.
31. Method according to claim 30, wherein the transcription activation is measured via the expression of the DNA coding for a protein.
32. Method according to claim 31 wherein the amount of the protein or an effect caused by the produced protein is determined.
33. Use of a transcription system according to claim 1 for the identification of a phosphatase or kinase agonist or antagonist.
34. Use of a transcription system according to claim 1 for the identification of a phosphatase or kinase antagonist.
35.A compound identified with the method according to claim 33 for use in a method of treatment.
36.A compound identified with the method according to claim 33 for use in a method of treatment that is characterized by inhibiting T-cell activation and/or prevention of graft rejection.
37. A pharmaceutical composition comprising one or more of the compounds identified with the method according to claim 33 or a pharmacologically acceptable salt thereof, optionally together with pharmacologically suitable carrier
PCT/EP1995/002724 1994-07-22 1995-07-12 Dual hybrid system WO1996003501A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP95925863A EP0775206A1 (en) 1994-07-22 1995-07-12 Dual hybrid system
JP8505403A JPH11506301A (en) 1994-07-22 1995-07-12 2-hybrid system
AU29832/95A AU2983295A (en) 1994-07-22 1995-07-12 Dual hybrid system
FI970205A FI970205A (en) 1994-07-22 1997-01-17 The two-hybrid system
NO970258A NO970258L (en) 1994-07-22 1997-01-21 Double hybrid system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94810435.1 1994-07-22
EP94810435 1994-07-22

Publications (1)

Publication Number Publication Date
WO1996003501A1 true WO1996003501A1 (en) 1996-02-08

Family

ID=8218290

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/002724 WO1996003501A1 (en) 1994-07-22 1995-07-12 Dual hybrid system

Country Status (6)

Country Link
EP (1) EP0775206A1 (en)
JP (1) JPH11506301A (en)
AU (1) AU2983295A (en)
FI (1) FI970205A (en)
NO (1) NO970258L (en)
WO (1) WO1996003501A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031113A1 (en) * 1996-02-23 1997-08-28 Ariad Pharmaceuticals, Inc. Cell-based assay
EP0830459A1 (en) * 1995-04-11 1998-03-25 The General Hospital Corporation Reverse two-hybrid systems
WO1998013502A2 (en) * 1996-09-27 1998-04-02 Icos Corporation Method to identify compounds for disrupting protein/protein interactions
WO1998026056A1 (en) * 1996-12-12 1998-06-18 Incyte Pharmaceuticals, Inc. Protein phosphatase regulatory subunit
US6365347B1 (en) * 1997-04-11 2002-04-02 The Regents Of The University Of California Method for identifying disruptors of biological pathways using genetic selection
EP1803427A1 (en) 2005-12-28 2007-07-04 The Procter and Gamble Company Absorbent Articles with Comfortable Elasticated Laminates
US7654993B2 (en) 2005-10-18 2010-02-02 The Procter And Gamble Company Absorbent articles with comfortable elasticated laminates
US7708728B2 (en) 2005-10-18 2010-05-04 The Procter & Gamble Company Absorbent articles with comfortable elasticated laminates
US7771406B2 (en) 2001-07-26 2010-08-10 The Procter & Gamble Company Articles with elasticated topsheets
US7794440B2 (en) 2002-11-08 2010-09-14 The Procter & Gamble Company Disposable absorbent articles with masking topsheet having one or more openings providing a passageway to a void space
US7905871B2 (en) 2003-10-02 2011-03-15 The Procter & Gamble Company Elasticated materials having bonding patterns used with low load force elastics and stiff carrier materials
US8333746B2 (en) 2007-02-13 2012-12-18 The Procter & Gamble Company Disposable absorbent article with separate part

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014780A1 (en) * 1992-01-28 1993-08-05 Abraham Karpas The use of a compound for the manufacture of a medicament for the treatment of hiv infection
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
WO1994009135A1 (en) * 1992-10-16 1994-04-28 Cold Spring Harbor Laboratory Cyclin complex rearrangement and uses related thereto
WO1994010300A1 (en) * 1992-10-30 1994-05-11 The General Hospital Corporation Interaction trap system for isolating novel proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
WO1993014780A1 (en) * 1992-01-28 1993-08-05 Abraham Karpas The use of a compound for the manufacture of a medicament for the treatment of hiv infection
WO1994009135A1 (en) * 1992-10-16 1994-04-28 Cold Spring Harbor Laboratory Cyclin complex rearrangement and uses related thereto
WO1994010300A1 (en) * 1992-10-30 1994-05-11 The General Hospital Corporation Interaction trap system for isolating novel proteins

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
B.E. KEMP AND R.B. PEARSON: "Protein kinase recognition sequence motifs", TRENDS IN BIOCHEMICAL SCIENCE, vol. 15, no. 9, ELSEVIER SCIENCE, AMSTERDAM, NL;, pages 342 - 346 *
CHAUDHURI, BHABATOSH ET AL: "The interaction between the catalytic A subunit of calcineurin and its autoinhibitory domain, in the yeast two-hybrid system, is disrupted by cyclosporin A and FK506", FEBS LETT. (1995), 357(2), 221-6 CODEN: FEBLAL;ISSN: 0014-5793 *
H. FLOTOW AND G. THOMAS: "Substrate recognition determinants of the mitogen-activated 70K S6 kinase from rat liver", J. BIOL. CHEM., vol. 267, no. 5, 15 February 1992 (1992-02-15), AM. SOC. MOL. BIOL., INC.,BALTIMORE, US;, pages 3074 - 3078 *
M. SERRANO ET AL.: "A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4", NATURE, vol. 366, 16 December 1993 (1993-12-16), MACMILLAN JOURNALS LTD., LONDON,UK, pages 704 - 707 *
M.S. CYERT ET AL.: "Yeast has homologs (CNA1 and CNA2 gene products) of mammalian calcineurin, a calmodulin-regulated phosphoprotein phosphatase", PROC. NATL. ACAD SCI., vol. 88, no. 16, 15 August 1991 (1991-08-15), NATL. ACAD SCI., WASHINGTON, DC, US;, pages 7376 - 7380 *
X. YANG ET AL.: "A protein kinase substrate identified by the two-hybrid system", SCIENCE, vol. 257, 31 July 1992 (1992-07-31), AAAS, WASHINGTON, DC, US;, pages 680 - 682 *
Y. HASHIMOTO ET AL.: "Identification of an autoinhibitory domain in calcineurin", J. BIOL. CHEM., vol. 265, no. 4, 5 February 1990 (1990-02-05), AM. SOC. MOL. BIOL., INC.,BALTIMORE, US;, pages 1924 - 1927 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601533B2 (en) 1995-04-11 2009-10-13 The General Hospital Corporation Reverse two-hybrid systems
EP0830459A1 (en) * 1995-04-11 1998-03-25 The General Hospital Corporation Reverse two-hybrid systems
EP0830459A4 (en) * 1995-04-11 2002-02-27 Gen Hospital Corp Reverse two-hybrid systems
US7033768B2 (en) 1995-04-11 2006-04-25 The General Hospital Corporation Reverse two-hybrid systems
WO1997031113A1 (en) * 1996-02-23 1997-08-28 Ariad Pharmaceuticals, Inc. Cell-based assay
WO1998013502A2 (en) * 1996-09-27 1998-04-02 Icos Corporation Method to identify compounds for disrupting protein/protein interactions
WO1998013502A3 (en) * 1996-09-27 1998-07-16 Icos Corp Method to identify compounds for disrupting protein/protein interactions
WO1998026056A1 (en) * 1996-12-12 1998-06-18 Incyte Pharmaceuticals, Inc. Protein phosphatase regulatory subunit
US6365347B1 (en) * 1997-04-11 2002-04-02 The Regents Of The University Of California Method for identifying disruptors of biological pathways using genetic selection
US7771406B2 (en) 2001-07-26 2010-08-10 The Procter & Gamble Company Articles with elasticated topsheets
US7794440B2 (en) 2002-11-08 2010-09-14 The Procter & Gamble Company Disposable absorbent articles with masking topsheet having one or more openings providing a passageway to a void space
US8414553B2 (en) 2002-11-08 2013-04-09 The Procter & Gamble Company Disposable absorbent article with masking topsheet having one or more openings providing a passageway to a void space
US7905871B2 (en) 2003-10-02 2011-03-15 The Procter & Gamble Company Elasticated materials having bonding patterns used with low load force elastics and stiff carrier materials
US7654993B2 (en) 2005-10-18 2010-02-02 The Procter And Gamble Company Absorbent articles with comfortable elasticated laminates
US7708728B2 (en) 2005-10-18 2010-05-04 The Procter & Gamble Company Absorbent articles with comfortable elasticated laminates
EP1803427A1 (en) 2005-12-28 2007-07-04 The Procter and Gamble Company Absorbent Articles with Comfortable Elasticated Laminates
US8663183B2 (en) 2005-12-28 2014-03-04 The Procter & Gamble Company Absorbent articles with comfortable elasticated laminates
US8333746B2 (en) 2007-02-13 2012-12-18 The Procter & Gamble Company Disposable absorbent article with separate part

Also Published As

Publication number Publication date
FI970205A0 (en) 1997-01-17
FI970205A (en) 1997-03-19
JPH11506301A (en) 1999-06-08
AU2983295A (en) 1996-02-22
NO970258L (en) 1997-03-03
NO970258D0 (en) 1997-01-21
EP0775206A1 (en) 1997-05-28

Similar Documents

Publication Publication Date Title
Stansfield et al. The products of the SUP45 (eRF1) and SUP35 genes interact to mediate translation termination in Saccharomyces cerevisiae.
West et al. Construction and analysis of yeast RNA polymerase II CTD deletion and substitution mutations.
James et al. Genomic libraries and a host strain designed for highly efficient two-hybrid selection in yeast
Lutfiyya et al. Two zinc-finger-containing repressors are responsible for glucose repression of SUC2 expression
CA2148252C (en) Interaction trap system for isolating novel proteins
Jansen et al. Drag&Drop cloning in yeast
Bartel et al. A protein linkage map of Escherichia coli bacteriophage T7
Le et al. Two new S‐phase‐specific genes from Saccharomyces cerevisiae
Brocard et al. The tetratricopeptide repeat domain of the PAS10 protein of Saccharomyces cerevisiae is essential for binding the peroxisomal targeting signal-SKL
Hirschhorn et al. A new class of histone H2A mutations in Saccharomyces cerevisiae causes specific transcriptional defects in vivo
Malathi et al. Interaction of yeast repressor-activator protein Ume6p with glycogen synthase kinase 3 homolog Rim11p
Park et al. Identification and characterization of the genes for two topoisomerase I‐interacting proteins from Saccharomyces cerevisiae
EP0773952A1 (en) Interaction trap systems for detecting protein interactions
EP0775206A1 (en) Dual hybrid system
Freeman et al. Molecular and genetic analysis of the toxic effect of RAP1 overexpression in yeast.
EP1053347B1 (en) Peptide detection method
Creasy et al. Molecular analysis of the PHO81 gene of Saccharomyces cerevisiae
US5677153A (en) Methods for modifying DNA and for detecting effects of such modification on interaction of encoded modified polypeptides with target substrates
KR20000057258A (en) Identification of inhibitors that prevent access of telomerase to chromosomal terminus
Klosterman et al. Ubc2, an ortholog of the yeast Ste50p adaptor, possesses a basidiomycete-specific carboxy terminal extension essential for pathogenicity independent of pheromone response
US5679566A (en) Yeast NMD2 gene
Shimizu et al. NBP1 (Nap1 binding protein 1), an essential gene for G2/M transition of Saccharomyces cerevisiae, encodes a protein of distinct sub-nuclear localization
Marykwas et al. Mapping by multifragment cloning in vivo.
Lee et al. Linker insertion mutagenesis of Drosophila topoisomerase II: probing the structure of eukaryotic topoisomerase II
US20090163370A1 (en) Competitive N-Hybrid System

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995925863

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 505403

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 970205

Country of ref document: FI

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 765551

Date of ref document: 19970122

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1995925863

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1995925863

Country of ref document: EP